amiodarone has been researched along with Recrudescence in 318 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ARTEMIS atrial fibrillation (AF) Loading and Long-term studies evaluated switching patients with paroxysmal/persistent AF from amiodarone to dronedarone." | 9.34 | Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. ( Bhatt, DL; Camm, AJ; Le Heuzey, JY; Lombardi, F; Martinez, JM; Naccarelli, GV; Naditch-Brûlé, L; Tamargo, J, 2020) |
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 9.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "The Short-term AMIOdarone treatment after CATheter ablation for atrial fibrillation (AMIO-CAT) trial randomized patients to 8 weeks of oral amiodarone or placebo following AF ablation." | 9.30 | QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial. ( Chen, X; Darkner, S; Diederichsen, SZ; Hansen, J; Johannessen, A; Pehrson, S; Svendsen, JH, 2019) |
| "Adjunctive short-term amiodarone therapy improves the success rate after catheter ablation of persistent atrial fibrillation during long-term follow-up." | 9.27 | Catheter ablation of persistent atrial fibrillation : Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome. ( Gramley, F; Kettering, K, 2018) |
| "The impact of amiodarone on ablation outcome in longstanding persistent atrial fibrillation (LSPAF) patients is not known yet." | 9.20 | Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). ( Al-Ahmad, A; Bai, R; Beheiry, S; Burkhardt, JD; Casella, M; Dello Russo, A; Di Biase, L; Forleo, G; Gallinghouse, JG; Hongo, R; Horton, R; Hranitzky, PM; Lakkireddy, D; Mohanty, P; Mohanty, S; Natale, A; Pelargonio, G; Reddy, M; Rossillo, A; Sanchez, JE; Santangeli, P; Themistoclakis, S; Tondo, C; Trivedi, C; Zagrodzky, J, 2015) |
| " 18 months of amiodarone treatment after atrial fibrillation (AF) conversion in patients who experienced the first episode of persistent AF." | 9.19 | Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months. ( Bonato, R; Chiale, PA; Elizari, MV; Galperin, J; Lago, M; Ledesma, R; Piasentin, J; Sanchez, J; Spada, P; Vazquez Blanco, M, 2014) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 9.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "Short-term oral amiodarone treatment following ablation for paroxysmal or persistent AF did not significantly reduce recurrence of atrial tachyarrhythmias at the 6-month follow-up, but it more than halved atrial arrhythmia related hospitalization and cardioversion rates during the blanking period." | 9.19 | Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). ( Chen, X; Darkner, S; Hansen, J; Johannessen, A; Nielsen, JB; Pehrson, S; Svendsen, JH, 2014) |
| "Amiodarone-induced thyrotoxicosis (AIT) type 2 is self-limiting in nature, but most physicians are reluctant to continue amiodarone." | 9.16 | Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. ( Dullaart, RP; Endert, E; Eskes, SA; Fliers, E; Geskus, RB; Links, TP; Wiersinga, WM, 2012) |
| "EPS was performed 1 month after starting amiodarone, and Holter-monitoring was recorded before and 1 month after amiodarone in 188 patients with sustained VT/VF because of structural heart diseases." | 9.13 | Electrophysiologic study-guided amiodarone for sustained ventricular tachyarrhythmias associated with structural heart diseases. ( Aiba, T; Aihara, N; Kamakura, S; Kurita, T; Noda, T; Okamura, H; Satomi, K; Shimizu, W; Suyama, K; Taguchi, A; Yamagata, K, 2008) |
| "The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR)." | 9.12 | Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. ( Chaveles, JI; Dagadaki, OK; Kafkas, NV; Kelesidis, KM; Mertzanos, GA; Papageorgiou, KI; Patsilinakos, SP, 2007) |
| "Amiodarone is effective in preventing the recurrence of atrial fibrillation (AF) after cardioversion (CV)." | 9.10 | Effect of amiodarone on dispersion of atrial refractoriness and cycle length in patients with atrial fibrillation. ( Armstrong, KL; Fitzpatrick, AP; Fynn, SP; Garratt, CJ; Hobbs, WJ; Todd, DM, 2003) |
| "As compared with lidocaine, amiodarone leads to substantially higher rates of survival to hospital admission in patients with shock-resistant out-of-hospital ventricular fibrillation." | 9.10 | Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. ( Barr, A; Cass, D; Cooper, R; Dorian, P; Gelaznikas, R; Schwartz, B, 2002) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 9.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "The efficacy of diltiazem or amiodarone pretreatment (oral, 1 month before and 1 month after conversion) on direct-current conversion of persistent atrial fibrillation was assessed in 120 patients, randomly assigned to 3 matched groups: A (n = 44, diltiazem); B (n = 46, amiodarone), and C (n = 30, digoxin)." | 9.09 | Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. ( Capucci, A; Piepoli, MF; Terracciano, C; Villani, GQ, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 9.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 9.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "In the Basel Antiarrhythmic Study of Infarct Survival trial, low-dose amiodarone improved 1-year survival in patients with asymptomatic complex ventricular arrhythmias persisting 2 weeks after myocardial infarction." | 9.07 | Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, ME, 1993) |
| "The new protocol of amiodarone was proposed to treat and to prevent some paroxysm and refractory arrhythmias with classic treatments." | 9.07 | [New amiodarone protocol in the treatment of refractory arrhythmias]. ( Abou Jaoudé, S; Checrallah, E; Halaby, J; Salamé, E, 1992) |
| "In order to compare the efficacy in preventing recurrencies of symptomatic atrial fibrillation of amiodarone (A." | 9.07 | [A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation]. ( Locati, F; Nava, S; Veniani, M; Villani, R; Zoletti, F, 1992) |
| "To study efficacy and safety of low-dose amiodarone for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation or flutter." | 9.07 | Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. ( Crijns, HJ; Gosselink, AT; Hillige, H; Lie, KI; Van Gelder, IC; Wiesfeld, AC, 1992) |
| "We examined the chronic electrophysiologic, systemic, and pharmacologic effects of chronic oral amiodarone therapy in 24 patients with refractory ventricular tachycardia and organic heart disease." | 9.05 | Chronic effects of amiodarone in patients with refractory ventricular tachycardia. ( Cappello, G; Rothbart, ST; Saksena, S, 1983) |
| "Thirty-three patients with recurrent drug-refractory ventricular tachycardia were treated with oral amiodarone during an average period of 6." | 9.05 | Antiarrhythmic efficacy of amiodarone in recurrent ventricular tachycardia evaluated by multiple electrophysiological and ambulatory ECG recordings. ( Griffin, J; Mason, J; Peters, F; Rasmussen, K; Ross, D; Winkle, R, 1982) |
| "Amiodarone, a benzofuranic iodine-rich pan-anti-arrhythmic drug, induces amiodarone-induced thyrotoxicosis (AIT) in 7-15% of patients." | 9.01 | Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature. ( Batisse-Lignier, M; Benichou, T; Dallel, S; Desbiez, F; Maqdasy, S; Montanier, N; Roche, B; Tauveron, I, 2019) |
| "To review the limitations of current antiarrhythmic drugs in atrial fibrillation (AF) and discuss the rationale and clinical trials supporting the use of ranolazine in AF." | 8.95 | Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation. ( Nguyen, E; White, CM, 2017) |
| "Oral amiodarone may be used in the prevention of recurrences of paroxysmal atrial fibrillation (AF) or in chronic AF following electrical cardioversion or for pharmacological cardioversion of AF." | 8.80 | Amiodarone in atrial fibrillation. ( Levy, S, 1998) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 8.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| "The present article reviews the experience with amiodarone therapy in life-threatening ventricular tachyarrhythmias." | 8.78 | Clinical efficacy of long-term treatment with amiodarone for life-threatening arrhythmias. ( Burckhardt, D, 1992) |
| "The use of amiodarone for postoperative atrial fibrillation (AF) is widespread; however, there is a paucity of data on the optimal duration of overlap when transitioning from intravenous (IV) to oral amiodarone." | 8.12 | Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery. ( Lam, JC; Lee, YG; Maurer, J; Patanwala, AE; Radosevich, JJ; Stevenson, B, 2022) |
| "Reintroduction of amiodarone in patients with a history of amiodarone-induced thyrotoxicosis (AIT) is rarely used." | 7.83 | Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. ( Auclair, C; Batisse-Lignier, M; Citron, B; Desbiez, F; Lusson, JR; Maqdasy, S; Roche, B; Tauveron, I; Thieblot, P, 2016) |
| "Amiodarone should be administered as a bolus dose followed immediately with an infusion when treating atrial fibrillation in the medical-surgical intensive care unit." | 7.83 | Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. ( Bandeshe, H; Boots, R; Clement, P; Mitrić, G; Udy, A, 2016) |
| "In this study, our aim is to examine the role of the neutrophil to lymphocyte ratio (NLR) in the predictions of recurrence under long-term follow-up in patients whose sinus rhythms (SRs) were restored with amiodarone in acute atrial fibrillation (AF)." | 7.81 | Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone. ( Karapınar, H; Karavelioğlu, Y; Kurt, R; Memiç, K; Sarak, T; Yilmaz, A; Yüksel, M, 2015) |
| " We analyzed 3 guidelines from medical specialty societies about dronedarone hydrochloride, an antiarrhythmic drug related to amiodarone hydrochloride, for treatment of patients with atrial fibrillation." | 7.80 | Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. ( Clarke, S; Flego, G; Haupt, E; Iannone, P; Magrini, N; Minardi, M; Truglio, P, 2014) |
| "Many patients with atrial fibrillation (AF) receive amiodarone." | 7.79 | Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study. ( Lebedev, AD; Lebedev, DS; Mikhaylov, EN; Orshanskaya, VS; Szili-Torok, T, 2013) |
| "The authors describe a case of a 74-year-old man with advanced coronary heart disease in whom pulmonary hemorrhagic complications during therapy with ticlopidine and subsequently with clopidogrel and amiodarone were observed." | 7.73 | [Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma]. ( Cofta, S; Elikowski, W; Mańczak, J; Nowicki, A; Psuja, P, 2005) |
| "The study analyzed the role of different variables that determine long-term sinus rhythm maintenance in patients with persistent atrial fibrillation who are treated with amiodarone." | 7.72 | Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance. ( Blanco, MV; Bonato, R; Chiale, PA; Elizari, MV; Galperín, J; Lago, M; Ledesma, R; Molina, RT; Scapín, AO, 2003) |
| "Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M = 12, F = 3, mean age: 63 +/- 14)." | 7.72 | Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. ( Arlot, S; Delonca, J; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Thyrotoxicosis is a well-documented and studied complication of treatment with amiodarone, but little has been written about the risks and treatment of recurrent thyrotoxicosis upon re-exposure to amiodarone." | 7.72 | Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? ( Braverman, LE; Cooper, DS; Kloos, RT; Ladenson, PW; Ryan, LE, 2004) |
| "Amioradone-induced hyperthyroidism is a common complication of amiodarone therapy." | 7.72 | [Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131]. ( Arlot, S; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not." | 7.72 | Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004) |
| "Low-dose amiodarone was safe and effective in restoring and maintaining SR in patients with AF and rheumatic heart disease." | 7.71 | Management of persistent atrial fibrillation following balloon mitral valvotomy: safety and efficacy of low-dose amiodarone. ( Kapoor, A; Kumar, S; Pandey, CM; Singh, RK; Sinha, N, 2002) |
| "To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction." | 7.71 | Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001) |
| "In 232 Japanese patients receiving long-term amiodarone therapy for life-threatening ventricular tachyarrhythmias, hyperthyroidism and hypothyroidism developed in 29 patients (12." | 7.71 | Amiodarone-Induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan. ( Hagiwara, N; Kasanuki, H; Matsuda, N; Sato, K; Shiga, T; Shoda, M; Wakaumi, M, 2001) |
| "The efficacy and safety of amiodarone in the management of atrial fibrillation (AF) or flutter in 108 Japanese patients with heart failure was retrospectively examined." | 7.71 | Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. ( Hagiwara, N; Hosaka, F; Imai, T; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Sugiura, R; Suzuki, T; Wakaumi, M; Yamada, Y, 2002) |
| " Large doses of catecholamines given during resuscitation, in the presence of butane, may cause recurrent ventricular fibrillation." | 7.70 | Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation. ( Edwards, KE; Wenstone, R, 2000) |
| "Ninety-one percent of patients with atrial fibrillation (AF) resisting electrical cardioversion because of immediate reinitiation of AF after the shock maintain long-term sinus rhythm with amiodarone and repeat cardioversion." | 7.70 | Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone. ( Crijns, HJ; Schoonderwoerd, BA; Van Gelder, IC; Van Noord, T, 2000) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 7.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| "The aim of our study was to assess (1) the effectiveness of repeat DC cardioversion in patients with chronic atrial fibrillation after pretreatment with amiodarone, and (2) the efficacy of amiodarone in maintaining sinus rhythm after repeat cardioversion." | 7.69 | Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. ( Górecki, A; Kraska, T; Opolski, G; Stanisławska, J; Swiecicka, G; Torbicki, A, 1997) |
| "Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence." | 7.68 | Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction. ( Facchin, D; Feruglio, GA; Proclemer, A; Vanuzzo, D, 1993) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 7.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 7.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 7.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "In 15 patients with recurrent ventricular tachycardia, the hemodynamic effects of amiodarone were evaluated under oral loading (1000 mg/day for 14-16 days) and during chronic treatment (600 mg/day for a further 10 weeks)." | 7.68 | Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia. ( Jung, W; Lüderitz, B; Manz, M, 1992) |
| "Intravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3." | 7.68 | Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. ( DonMichael, TA; Ismail, Y; Nalos, PC; Nyitray, W; Pappas, JM, 1991) |
| "The long-term follow-up of 52 pts (36 M, 16 F, mean age: 62 years) with sustained ventricular tachyarrhythmias (SVT) was analyzed to assess the efficacy and feasibility of empiric amiodarone treatment." | 7.68 | [Empiric treatment with amiodarone in patients with sustained ventricular tachyarrhythmia. Results of a long-term follow-up]. ( Bonso, A; Caprioglio, F; D'Este, D; Delise, P; Di Pede, F; Gasparini, G; Piccolo, E; Raviele, A; Zanocco, A, 1990) |
| "To evaluate the efficacy and safety of long-term empiric amiodarone therapy in patients with recurrent Sustained Ventricular Tachycardia (SVT) and Chronic Chagasic Myocarditis (CCM)." | 7.68 | [Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia]. ( Bellotti, G; Lee, JH; Pileggi, F; Scanavacca, MI; Sosa, EA, 1990) |
| "Amiodarone in a low dose (200 mg/day) was administered alone or in combination with other type I antiarrhythmic drugs as a first-line agent in 33 patients with ventricular tachycardia (VT) (n = 24) or ventricular fibrillation (VF) (n = 9) secondary to coronary artery disease with healed myocardial infarction." | 7.68 | Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone. ( Kusniec, J; Mager, A; Sclarovsky, S; Strasberg, B; Zlotikamien, B, 1990) |
| "The determinants of long-term clinical outcome were studied in 42 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) who were treated with amiodarone as the sole antiarrhythmic agent." | 7.67 | Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. ( DiMarco, JP; Garan, H; Grant, G; Malacoff, RF; McGovern, B; Ruskin, JN; Sellers, TD, 1984) |
| "Verapamil is a calcium channel blocker ideally suited for the treatment of A-V nodal reciprocating supraventricular tachycardia." | 7.67 | [Idiopathic recurrent ventricular tachycardia: role of verapamil in its treatment]. ( Arriagada, C; Fajuri, A; González, R; Marchesse, M; Serrat, H, 1989) |
| "The clinical efficacy of intravenous amiodarone in terminating sustained ventricular tachycardia and in preventing recurrences of ventricular tachycardia and ventricular fibrillation was evaluated in 26 patients." | 7.67 | Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. ( Harringer, W; Herbinger, W; Kerschner, K; Leisch, F; Schützenberger, W, 1989) |
| "Amiodarone was used in 86 patients with ventricular tachycardia (VT) (67 patients) or ventricular fibrillation (19 patients) secondary to coronary artery disease." | 7.67 | Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone. ( Estes, NA; Manolis, AS; Uricchio, F, 1989) |
| "The antiarrhythmic efficacy and safety of intravenous amiodarone were evaluated in 13 patients with recurrent sustained ventricular tachycardia." | 7.67 | Efficacy of intravenous amiodarone as short-term treatment for refractory ventricular tachycardia. ( Klein, RC; Machell, C; Rushforth, N; Standefur, J, 1988) |
| "Induction of ventricular tachycardia (VT) at electrophysiologic study in patients taking amiodarone poorly predicts recurrence of VT." | 7.67 | Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrop ( Chang, MS; Fineberg, N; Heger, JJ; Kammerling, JM; Klein, LS; Miles, WM; Prystowsky, EN; Zipes, DP, 1988) |
| "The relation of clinical and electrophysiologic variables to outcome was evaluated in 121 patients treated with amiodarone for sustained ventricular tachyarrhythmias." | 7.67 | Usefulness of electrophysiologic study to determine the clinical tolerance of arrhythmia recurrences during amiodarone therapy. ( Buxton, AE; Flores, B; Josephson, ME; Kadish, AH; Marchlinski, FE; Waxman, HL, 1987) |
| "Thirty-three patients with clinically recurrent ventricular tachyarrhythmias were treated with amiodarone (200 to 600 mg/day) during a mean follow-up period of 23." | 7.67 | Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment. ( Brachmann, J; Kübler, W; Rizos, I; Schmitt, C; Senges, J; Waldecker, B, 1987) |
| "The value of serial electropharmacologic testing during long-term oral amiodarone therapy for prediction of long-term drug efficacy as well as characteristics of arrhythmia recurrence is controversial." | 7.67 | Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. ( DiMarco, JP; Haines, DE; Lerman, BB; Zhu, J, 1987) |
| "We examined the value of clinical variables, chronic 24-hour ambulatory ECG monitoring, and chronic electrophysiologic (EP) testing in 49 patients with recurrent and refractory sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) treated with chronic oral amiodarone in order to develop a prospective approach to the management of these patients." | 7.67 | Management of refractory sustained ventricular tachycardia with amiodarone: a reappraisal. ( Lavery, D; Saksena, S, 1987) |
| "Ventricular tachycardia induced by programmed electrical stimulation during amiodarone therapy often does not preclude a good clinical response." | 7.67 | Amiodarone: risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. ( Duncan, G; Fineberg, NS; Heger, JJ; Naccarelli, GV; Prystowsky, EN; Zipes, DP, 1985) |
| "Over a 10-year period 130 patients with drug-resistant cardiac arrhythmias associated mainly with coronary artery disease and its complications were treated with amiodarone." | 7.67 | Amiodarone for refractory cardiac arrhythmias: 10-year study. ( Eydt, JN; Leak, D, 1986) |
| "The prognostic implications of changes in ventricular ectopic activity on serial 24 hour ambulatory electrocardiographic (Holter) recordings were prospectively evaluated in 107 patients with a history of sustained ventricular tachyarrhythmias treated with amiodarone for at least 30 days." | 7.67 | Utility of ambulatory electrocardiographic monitoring for predicting recurrence of sustained ventricular tachyarrhythmias in patients receiving amiodarone. ( Brady, PM; Greenspan, AM; Horowitz, LN; Kay, HR; Rae, AP; Sokoloff, NM; Spielman, SR, 1986) |
| "The prognostic importance of electrophysiologic studies in patients with sustained ventricular tachyarrhythmias treated with amiodarone was prospectively studied in 100 consecutive patients." | 7.67 | Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. ( Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Rae, AP; Rotmensch, H; Segal, BL; Sokoloff, NM; Spielman, SR; Webb, CR, 1985) |
| "Multivariate analysis of 11 clinical variables was performed in 104 patients with sustained, symptomatic ventricular tachycardia (VT) or ventricular fibrillation treated with amiodarone to determine variables predictive of subsequent cardiac arrest or sudden death." | 7.67 | Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. ( Davis, JC; DiCarlo, LA; Evans-Bell, T; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Winston, SA, 1985) |
| "Thirteen patients with refractory, recurrent, life-threatening ventricular tachycardia (VT) underwent electrophysiologic testing before and after long-term amiodarone therapy." | 7.67 | Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. ( Griffith, LS; Platia, EV; Reid, PR; Veltri, EP, 1985) |
| "Seventy-four patients with sustained ventricular tachyarrhythmias had 22 +/- 3 hours of Holter monitoring before and after 11 +/- 6 days of amiodarone treatment." | 7.67 | Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone. ( Buxton, AE; Doherty, JU; Flores, BT; Josephson, ME; Marchlinski, FE; Waxman, HL, 1985) |
| "We tested the efficacy of intravenous amiodarone (5 mg/kg) in slowing ventricular response and/or restoring sinus rhythm in 26 patients with paroxysmal or new atrial fibrillation with fast ventricular response." | 7.67 | Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. ( Agmon, J; Arditti, A; Buimovici, B; Lewin, RF; Sclarovsky, S; Strasberg, B, 1985) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 7.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "Twenty-three patients with sustained, recurrent, symptomatic ventricular tachycardia were treated with oral amiodarone." | 7.66 | Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. ( Girotti, LA; Kaski, JC; Messuti, H; Rosenbaum, MB; Rutitzky, B, 1981) |
| "Ninety-six patients with life-threatening ventricular arrhythmias refractory to two or more conventional agents were treated with amiodarone and followed for 6 to 40 months (mean, 15 months)." | 7.66 | Amiodarone in refractory life-threatening ventricular arrhythmias. ( Cannom, DS; Feld, G; Hendrickson, J; Intarachot, V; Lopez, B; Nademanee, K; Singh, BN; Weiss, JL, 1983) |
| "Amiodarone was used in 30 patients with tachyarrhythmias refractory to treatment with several antiarrhythmic agents." | 7.66 | Amiodarone in long term management of refractory cardiac tachyarrhythmias. ( Lowe, JB; Lubbe, WF; Mercer, CJ; Roche, AH, 1981) |
| "Nine patients with life-threatening ventricular arrhythmias were administered oral amiodarone over a period of months." | 7.66 | Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. ( Finerman, WB; Hamer, AW; Mandel, WJ; Peter, T, 1981) |
| "A combined mexiletine and amiodarone treatment was applied in nine cases with recurrent refractory ventricular tachycardia." | 7.66 | Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. ( Demoulin, JC; Kulbertus, HE; Legrand, V; Mary-Rabine, L; Waleffe, A, 1980) |
| "Amiodarone hydrochloride was used to treat 19 patients with symptomatic arrhythmias refractory to quinidine sulfate, procainamide hydrochloride, disopyramide phosphate, antazoline hydrochloride, lidocaine hydrochloride, bretylium tosylate, propranolol hydrochloride, phenytoin sodium, and practotol acetanilide given to the limit of tolerance." | 7.66 | Control of refractory cardiac arrhythmias with amiodarone. ( Eydt, JN; Leak, D, 1979) |
| "Neiguan point acupuncture combined with amiodarone is superior to amiodarone alone in reducing early recurrences of patients with persistent AF after PVI." | 6.90 | Effect of acupuncture at Neiguan point combined with amiodarone therapy on early recurrence after pulmonary vein electrical isolation in patients with persistent atrial fibrillation. ( Bao, M; Dong, L; Fu, H; He, B; Huang, C; Huang, H; Liu, H; Liu, X; Liu, Y; Lu, Z; Wu, G; Yang, B; Yang, M; Yin, J; Yu, S; Zhao, Q, 2019) |
| "Amiodarone was discontinued in 18 patients randomized to amiodarone for side effects, bradycardia, or noncompliance." | 6.82 | Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial. ( Ad, N; Holmes, SD; Miller, CE; Pritchard, G; Shuman, DJ, 2016) |
| "The primary end-point was recurrence of AF." | 6.75 | Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement. ( Cai, J; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X; Wusha, D; Xie, S, 2010) |
| "Amiodarone was employed as the anti-arrhythmic drug during the first 18 months, and diltiazem in the second half of the study." | 6.73 | Postoperative outcome of patients undergoing lung resection presenting with new-onset atrial fibrillation managed by amiodarone or diltiazem. ( Ampollini, L; Bettati, S; Bobbio, A; Caporale, D; Carbognani, P; Internullo, E; Rossini, E; Rusca, M, 2007) |
| "Amiodarone was administered as the third antiarrhythmic agent to patients who had AF recurrence on the first two antiarrhythmic agents (propafenone, sotalol or disopyramide)." | 6.71 | Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study. ( Kosior, DA; Opolski, G; Rabczenko, D; Wozakowska-Kaplon, B, 2005) |
| "Amiodarone and verapamil have been employed to treat immediate recurrences of AF (IRAF) after cardioversion." | 6.71 | Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Behrens, S; Kamke, W; Stahn, A; Sticherling, C; Zabel, M, 2005) |
| "If immediate recurrences of AF occurred 2 more times, the alternative study drug was administered, and cardioversion was repeated." | 6.70 | Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation. ( Chugh, A; Greenstein, R; Hassan, S; Knight, BP; Lai, SW; Morady, F; Oral, H; Ozaydin, M; Pelosi, F; Scharf, C; Strickberger, SA; Tada, H, 2002) |
| "51 ± 38." | 5.62 | Frontal plane QRS-T angle predicts early recurrence of acute atrial fibrillation after successful pharmacological cardioversion with intravenous amiodarone. ( Celik, A; Eyuboglu, M, 2021) |
| "However, late recurrences are more common compared to paroxAF." | 5.51 | Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy. ( Benák, A; Bencsik, G; Herczeg, A; Kohári, M; Makai, A; Pap, R; Sághy, L, 2019) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 5.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| "Perinatal atrial flutter is a serious arrhythmia." | 5.42 | [Repeated electrical cardioversions and amiodarone for recurrent neonatal atrial flutter]. ( Crochelet, AS; Jacquemart, C; Massin, M, 2015) |
| "Transient hypothyroidism was observed in only two patients (5%) with AIH, though was not observed in TMNG." | 5.35 | Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). ( Bartkowiak, Z; Czarnywojtek, A; Czepczynski, R; Florek, E; Ruchala, M; Sowinski, J; Szczepanek, E; Wasko, R; Zamyslowska, H; Zgorzalewicz-Stachowiak, M, 2009) |
| "The ARTEMIS atrial fibrillation (AF) Loading and Long-term studies evaluated switching patients with paroxysmal/persistent AF from amiodarone to dronedarone." | 5.34 | Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. ( Bhatt, DL; Camm, AJ; Le Heuzey, JY; Lombardi, F; Martinez, JM; Naccarelli, GV; Naditch-Brûlé, L; Tamargo, J, 2020) |
| "Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF)." | 5.34 | Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study. ( Chen, L; Chen, X; Fan, L; Gong, K; Huang, R; Lin, J; Xu, Z; Zhang, F; Zhang, Y, 2020) |
| "During follow-up a recurrence rate of 33% was observed in Group 1 (6 recurrences in 18 patients; p < 0." | 5.32 | Previous therapy with amiodarone increases the recurrence rate in successfully ablated patients with isthmus-dependent atrial flutter. ( Elvas, L; Providência, L; Ventura, M, 2004) |
| "The Short-term AMIOdarone treatment after CATheter ablation for atrial fibrillation (AMIO-CAT) trial randomized patients to 8 weeks of oral amiodarone or placebo following AF ablation." | 5.30 | QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial. ( Chen, X; Darkner, S; Diederichsen, SZ; Hansen, J; Johannessen, A; Pehrson, S; Svendsen, JH, 2019) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 5.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Amiodarone was discontinued because of side effects in 14%, 26% and 37% of patients after 1, 3 and 5 years, respectively." | 5.28 | Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. ( Goldberg, H; Griffin, JC; Helmy, I; Herre, JM; Langberg, JJ; Malone, P; Sauve, MJ; Scheinman, MM, 1989) |
| "Adjunctive short-term amiodarone therapy improves the success rate after catheter ablation of persistent atrial fibrillation during long-term follow-up." | 5.27 | Catheter ablation of persistent atrial fibrillation : Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome. ( Gramley, F; Kettering, K, 2018) |
| "TWelve patients had overt congestive heart failure." | 5.27 | Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia. ( DiCarlo, L; Morady, F; Scheinman, MM; Shapiro, W; Shen, E; Sung, RJ, 1983) |
| "Amiodarone was used in the treatment of 21 patients with supraventricular or ventricular arrhythmias which were refractory to conventional antiarrhythmic drugs, individually or in combination." | 5.27 | Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias. ( Best, JF; Dunn, M; Lynch, L; Rinkenberger, R, 1986) |
| "Amiodarone was administered in a loading dose of 1." | 5.27 | Treatment of ventricular arrhythmia after corrective cardiac surgery in a neonate with intravenous amiodarone. ( Bogers, AJ; Huysmans, HA; Ottenkamp, J; Quaegebeur, JM, 1987) |
| "The impact of amiodarone on ablation outcome in longstanding persistent atrial fibrillation (LSPAF) patients is not known yet." | 5.20 | Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE). ( Al-Ahmad, A; Bai, R; Beheiry, S; Burkhardt, JD; Casella, M; Dello Russo, A; Di Biase, L; Forleo, G; Gallinghouse, JG; Hongo, R; Horton, R; Hranitzky, PM; Lakkireddy, D; Mohanty, P; Mohanty, S; Natale, A; Pelargonio, G; Reddy, M; Rossillo, A; Sanchez, JE; Santangeli, P; Themistoclakis, S; Tondo, C; Trivedi, C; Zagrodzky, J, 2015) |
| " 18 months of amiodarone treatment after atrial fibrillation (AF) conversion in patients who experienced the first episode of persistent AF." | 5.19 | Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months. ( Bonato, R; Chiale, PA; Elizari, MV; Galperin, J; Lago, M; Ledesma, R; Piasentin, J; Sanchez, J; Spada, P; Vazquez Blanco, M, 2014) |
| "Our objective was to compare the efficacy of dronedarone and propafenone in maintaining sinus rhythm in patients with atrial fibrillation (AF) after electrical cardioversion." | 5.19 | Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. ( Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ, 2014) |
| "Short-term oral amiodarone treatment following ablation for paroxysmal or persistent AF did not significantly reduce recurrence of atrial tachyarrhythmias at the 6-month follow-up, but it more than halved atrial arrhythmia related hospitalization and cardioversion rates during the blanking period." | 5.19 | Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). ( Chen, X; Darkner, S; Hansen, J; Johannessen, A; Nielsen, JB; Pehrson, S; Svendsen, JH, 2014) |
| "Amiodarone-induced thyrotoxicosis (AIT) type 2 is self-limiting in nature, but most physicians are reluctant to continue amiodarone." | 5.16 | Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. ( Dullaart, RP; Endert, E; Eskes, SA; Fliers, E; Geskus, RB; Links, TP; Wiersinga, WM, 2012) |
| "EPS was performed 1 month after starting amiodarone, and Holter-monitoring was recorded before and 1 month after amiodarone in 188 patients with sustained VT/VF because of structural heart diseases." | 5.13 | Electrophysiologic study-guided amiodarone for sustained ventricular tachyarrhythmias associated with structural heart diseases. ( Aiba, T; Aihara, N; Kamakura, S; Kurita, T; Noda, T; Okamura, H; Satomi, K; Shimizu, W; Suyama, K; Taguchi, A; Yamagata, K, 2008) |
| "A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein ablation." | 5.12 | Circumferential pulmonary-vein ablation for chronic atrial fibrillation. ( Agricola, E; Augello, G; Bates, ER; Bogun, F; Chugh, A; Good, E; Lehmann, MH; Morady, F; Oral, H; Pappone, C; Pelosi, F; Sala, S; Santinelli, V; Vicedomini, G, 2006) |
| "The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR)." | 5.12 | Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. ( Chaveles, JI; Dagadaki, OK; Kafkas, NV; Kelesidis, KM; Mertzanos, GA; Papageorgiou, KI; Patsilinakos, SP, 2007) |
| "Determination of neurophysiological features of the disease course in patients with paroxysmal atrial fibrillation (AF); pathogenetic validation of use and assessment of therapeutic efficacy of clonazepam (an atypical agonist of benzodiazepine receptors) in combined antiarrhythmic therapy." | 5.12 | [New facts about pathogenesis of atrial fibrillation: correlation between changes in bioelectric brain activity and recurrence of atrial fibrillation paroxysms]. ( Fedorova, VI; Gordeev, SA; Nedostup, AV; Vasiukov, SS, 2007) |
| "Patients treated with amiodarone plus irbesartan had a lower rate of recurrence of atrial fibrillation than did patients treated with amiodarone alone." | 5.10 | Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. ( Bernal, E; Bueno, MG; Cabeza, P; Cano, JM; Cano, L; Madrid, AH; Marín, I; Moro, C; Peña, G; Rebollo, JM; Rodriguez, A, 2002) |
| "Amiodarone is effective in preventing the recurrence of atrial fibrillation (AF) after cardioversion (CV)." | 5.10 | Effect of amiodarone on dispersion of atrial refractoriness and cycle length in patients with atrial fibrillation. ( Armstrong, KL; Fitzpatrick, AP; Fynn, SP; Garratt, CJ; Hobbs, WJ; Todd, DM, 2003) |
| "As compared with lidocaine, amiodarone leads to substantially higher rates of survival to hospital admission in patients with shock-resistant out-of-hospital ventricular fibrillation." | 5.10 | Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. ( Barr, A; Cass, D; Cooper, R; Dorian, P; Gelaznikas, R; Schwartz, B, 2002) |
| "To assess and compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation." | 5.09 | Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. ( Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Simantirakis, EN; Vardas, PE, 2000) |
| "The efficacy of diltiazem or amiodarone pretreatment (oral, 1 month before and 1 month after conversion) on direct-current conversion of persistent atrial fibrillation was assessed in 120 patients, randomly assigned to 3 matched groups: A (n = 44, diltiazem); B (n = 46, amiodarone), and C (n = 30, digoxin)." | 5.09 | Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. ( Capucci, A; Piepoli, MF; Terracciano, C; Villani, GQ, 2000) |
| "This randomized study compared the efficacy and safety of amiodarone, propafenone and sotalol in the prevention of atrial fibrillation." | 5.09 | Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? ( Chrysostomakis, SI; Igoumenidis, NE; Kaleboubas, MD; Kochiadakis, GE; Marketou, ME; Mavrakis, HE; Vardas, PE, 2000) |
| "To compare the safety and efficacy of amiodarone and sotalol in the treatment of patients with recurrent symptomatic atrial fibrillation (AF), 70 patients were entered into a randomized, double-blind study." | 5.08 | Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. ( Igoumenidis, NE; Kanoupakis, EM; Kochiadakis, GE; Marketou, ME; Solomou, MC; Vardas, PE, 1998) |
| "In the Basel Antiarrhythmic Study of Infarct Survival trial, low-dose amiodarone improved 1-year survival in patients with asymptomatic complex ventricular arrhythmias persisting 2 weeks after myocardial infarction." | 5.07 | Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, ME, 1993) |
| "The new protocol of amiodarone was proposed to treat and to prevent some paroxysm and refractory arrhythmias with classic treatments." | 5.07 | [New amiodarone protocol in the treatment of refractory arrhythmias]. ( Abou Jaoudé, S; Checrallah, E; Halaby, J; Salamé, E, 1992) |
| "In order to compare the efficacy in preventing recurrencies of symptomatic atrial fibrillation of amiodarone (A." | 5.07 | [A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation]. ( Locati, F; Nava, S; Veniani, M; Villani, R; Zoletti, F, 1992) |
| "To study efficacy and safety of low-dose amiodarone for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation or flutter." | 5.07 | Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. ( Crijns, HJ; Gosselink, AT; Hillige, H; Lie, KI; Van Gelder, IC; Wiesfeld, AC, 1992) |
| "We examined the chronic electrophysiologic, systemic, and pharmacologic effects of chronic oral amiodarone therapy in 24 patients with refractory ventricular tachycardia and organic heart disease." | 5.05 | Chronic effects of amiodarone in patients with refractory ventricular tachycardia. ( Cappello, G; Rothbart, ST; Saksena, S, 1983) |
| "Thirty-three patients with recurrent drug-refractory ventricular tachycardia were treated with oral amiodarone during an average period of 6." | 5.05 | Antiarrhythmic efficacy of amiodarone in recurrent ventricular tachycardia evaluated by multiple electrophysiological and ambulatory ECG recordings. ( Griffin, J; Mason, J; Peters, F; Rasmussen, K; Ross, D; Winkle, R, 1982) |
| "Amiodarone, a benzofuranic iodine-rich pan-anti-arrhythmic drug, induces amiodarone-induced thyrotoxicosis (AIT) in 7-15% of patients." | 5.01 | Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature. ( Batisse-Lignier, M; Benichou, T; Dallel, S; Desbiez, F; Maqdasy, S; Montanier, N; Roche, B; Tauveron, I, 2019) |
| "To review the limitations of current antiarrhythmic drugs in atrial fibrillation (AF) and discuss the rationale and clinical trials supporting the use of ranolazine in AF." | 4.95 | Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation. ( Nguyen, E; White, CM, 2017) |
| "Oral amiodarone may be used in the prevention of recurrences of paroxysmal atrial fibrillation (AF) or in chronic AF following electrical cardioversion or for pharmacological cardioversion of AF." | 4.80 | Amiodarone in atrial fibrillation. ( Levy, S, 1998) |
| " In patients with a history of resuscitated ventricular fibrillation (VF) or unstable ventricular tachycardia (VT), the ICD was superior to therapy with amiodarone in 3 large trials involving 2,024 patients." | 4.80 | Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation. ( Hohnloser, SH, 1999) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 4.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| "Among the drugs recommended to prevent recurrences of atrial fibrillation after external electric shock, antiarrhythmic agents of classes Ia (quinidine, disopyramide), Ic (cibenzoline, flecainide, propafenone) and III (sotalol) seem to have the same effectiveness in maintaining the sinus rhythm in about 50 percent of the cases after 6 months and one year." | 4.78 | [Antiarrhythmic treatment after reduction of atrial fibrillation by external shock]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R, 1993) |
| "The present article reviews the experience with amiodarone therapy in life-threatening ventricular tachyarrhythmias." | 4.78 | Clinical efficacy of long-term treatment with amiodarone for life-threatening arrhythmias. ( Burckhardt, D, 1992) |
| "The use of amiodarone for postoperative atrial fibrillation (AF) is widespread; however, there is a paucity of data on the optimal duration of overlap when transitioning from intravenous (IV) to oral amiodarone." | 4.12 | Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery. ( Lam, JC; Lee, YG; Maurer, J; Patanwala, AE; Radosevich, JJ; Stevenson, B, 2022) |
| "Providing IV and PO overlap of amiodarone for a median of 4 hours did not decrease the rate of early tachyarrhythmia recurrence." | 3.91 | Clinical effects of intravenous to oral amiodarone transition strategies in critically ill adult patients. ( Aberle, C; Altshuler, D; Arnouk, S; Merchan, C; Papadopoulos, J; Piper, GL, 2019) |
| " Repeat CT chest after 2 weeks for recurrent cough showed a small PE, treated with oral prednisone for suspected postablation pericarditis, with complete resolution of cough." | 3.88 | Cough as the sole manifestation of pericardial effusion. ( Abdullah, O; Fong, HK; Gautam, S, 2018) |
| "Reintroduction of amiodarone in patients with a history of amiodarone-induced thyrotoxicosis (AIT) is rarely used." | 3.83 | Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. ( Auclair, C; Batisse-Lignier, M; Citron, B; Desbiez, F; Lusson, JR; Maqdasy, S; Roche, B; Tauveron, I; Thieblot, P, 2016) |
| "Amiodarone should be administered as a bolus dose followed immediately with an infusion when treating atrial fibrillation in the medical-surgical intensive care unit." | 3.83 | Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. ( Bandeshe, H; Boots, R; Clement, P; Mitrić, G; Udy, A, 2016) |
| "In this study, our aim is to examine the role of the neutrophil to lymphocyte ratio (NLR) in the predictions of recurrence under long-term follow-up in patients whose sinus rhythms (SRs) were restored with amiodarone in acute atrial fibrillation (AF)." | 3.81 | Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone. ( Karapınar, H; Karavelioğlu, Y; Kurt, R; Memiç, K; Sarak, T; Yilmaz, A; Yüksel, M, 2015) |
| " We analyzed 3 guidelines from medical specialty societies about dronedarone hydrochloride, an antiarrhythmic drug related to amiodarone hydrochloride, for treatment of patients with atrial fibrillation." | 3.80 | Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. ( Clarke, S; Flego, G; Haupt, E; Iannone, P; Magrini, N; Minardi, M; Truglio, P, 2014) |
| "We investigated the effect of amiodarone (AMD) administered intravenously for the treatment of post-operative atrial fibrillation( POAF) after cardiac surgery." | 3.80 | [Therapeutic use of amiodarone against postoperative fibrillation after cardiac surgery]. ( Araki, E; Kawaharada, N; Muraki, S; Nakashima, S; Osawa, H; Sakurada, T; Sasaki, J, 2014) |
| "The clinical efficacy in preventing the recurrence of atrial fibrillation (AF) is higher for amiodarone than for dronedarone." | 3.80 | In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology. ( Barthel, P; Dössel, O; Loewe, A; Lutz, Y; Schmidt, G; Scholz, EP; Seemann, G; Sinnecker, D; Wilhelms, M, 2014) |
| "Retrospective analysis of 2 double-blind, parallel-group trials (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and safety of dronedarone with placebo over 12 months." | 3.80 | Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. ( Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014) |
| "Many patients with atrial fibrillation (AF) receive amiodarone." | 3.79 | Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study. ( Lebedev, AD; Lebedev, DS; Mikhaylov, EN; Orshanskaya, VS; Szili-Torok, T, 2013) |
| "Multiple studies have shown that amiodarone is effective in treating atrial fibrillation (AF), but is associated with a relatively high incidence of side effects; however, due to amiodarone's long elimination half-life (20-100 days), physicians may hesitate to start other drugs until it has fully cleared." | 3.79 | Effects of dronedarone started rapidly after amiodarone discontinuation. ( Aliot, E; Capucci, A; Connolly, S; Crijns, H; Hohnloser, S; Immordino, L; Kowey, P; Radzik, D; Roy, D, 2013) |
| "Accidental intravascular administration of bupivacaine during performance of a brachial block precipitated convulsions followed by asystole." | 3.75 | Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest. ( Coetzee, AR; Levin, AI; Marwick, PC, 2009) |
| "The authors describe a case of a 74-year-old man with advanced coronary heart disease in whom pulmonary hemorrhagic complications during therapy with ticlopidine and subsequently with clopidogrel and amiodarone were observed." | 3.73 | [Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma]. ( Cofta, S; Elikowski, W; Mańczak, J; Nowicki, A; Psuja, P, 2005) |
| "Consecutive patients with persistent atrial fibrillation of at least 1 months' duration were included prospectively in a cardioversion protocol that involved standard antiarrhythmic pretreatment, with amiodarone being offered first, and follow-up." | 3.73 | [Therapeutic success of a prospective cardioversion protocol for persistent atrial fibrillation]. ( Ferrero, A; García-Civera, R; Llácer, A; Martínez-Brotóns, AM; Morell, S; Plancha, E; Roselló, A; Ruiz-Granell, R, 2006) |
| "The study analyzed the role of different variables that determine long-term sinus rhythm maintenance in patients with persistent atrial fibrillation who are treated with amiodarone." | 3.72 | Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance. ( Blanco, MV; Bonato, R; Chiale, PA; Elizari, MV; Galperín, J; Lago, M; Ledesma, R; Molina, RT; Scapín, AO, 2003) |
| "Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M = 12, F = 3, mean age: 63 +/- 14)." | 3.72 | Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. ( Arlot, S; Delonca, J; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Thyrotoxicosis is a well-documented and studied complication of treatment with amiodarone, but little has been written about the risks and treatment of recurrent thyrotoxicosis upon re-exposure to amiodarone." | 3.72 | Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? ( Braverman, LE; Cooper, DS; Kloos, RT; Ladenson, PW; Ryan, LE, 2004) |
| "Amioradone-induced hyperthyroidism is a common complication of amiodarone therapy." | 3.72 | [Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131]. ( Arlot, S; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not." | 3.72 | Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004) |
| "Although chronic amiodarone has been proven to be effective to suppress ventricular tachycardia (VT) and ventricular fibrillation (VF), how we predict the recurrence of VT/VF after chronic amiodarone remains unknown." | 3.72 | Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone. ( Aiba, T; Aihara, N; Inagaki, M; Kamakura, S; Kurita, T; Satomi, K; Shimizu, W; Sunagawa, K; Suyama, K; Taguchi, A, 2004) |
| "Low-dose amiodarone was safe and effective in restoring and maintaining SR in patients with AF and rheumatic heart disease." | 3.71 | Management of persistent atrial fibrillation following balloon mitral valvotomy: safety and efficacy of low-dose amiodarone. ( Kapoor, A; Kumar, S; Pandey, CM; Singh, RK; Sinha, N, 2002) |
| "To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction." | 3.71 | Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001) |
| "In 232 Japanese patients receiving long-term amiodarone therapy for life-threatening ventricular tachyarrhythmias, hyperthyroidism and hypothyroidism developed in 29 patients (12." | 3.71 | Amiodarone-Induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan. ( Hagiwara, N; Kasanuki, H; Matsuda, N; Sato, K; Shiga, T; Shoda, M; Wakaumi, M, 2001) |
| "The efficacy and safety of amiodarone in the management of atrial fibrillation (AF) or flutter in 108 Japanese patients with heart failure was retrospectively examined." | 3.71 | Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. ( Hagiwara, N; Hosaka, F; Imai, T; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Sugiura, R; Suzuki, T; Wakaumi, M; Yamada, Y, 2002) |
| " Large doses of catecholamines given during resuscitation, in the presence of butane, may cause recurrent ventricular fibrillation." | 3.70 | Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation. ( Edwards, KE; Wenstone, R, 2000) |
| "Ninety-one percent of patients with atrial fibrillation (AF) resisting electrical cardioversion because of immediate reinitiation of AF after the shock maintain long-term sinus rhythm with amiodarone and repeat cardioversion." | 3.70 | Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone. ( Crijns, HJ; Schoonderwoerd, BA; Van Gelder, IC; Van Noord, T, 2000) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 3.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| "The aim of our study was to assess (1) the effectiveness of repeat DC cardioversion in patients with chronic atrial fibrillation after pretreatment with amiodarone, and (2) the efficacy of amiodarone in maintaining sinus rhythm after repeat cardioversion." | 3.69 | Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. ( Górecki, A; Kraska, T; Opolski, G; Stanisławska, J; Swiecicka, G; Torbicki, A, 1997) |
| " Data also suggest that amiodarone appears to be the safest antiarrhythmic drug for treatment sustained and nonsustained arrhythmias, and improved survival in patients with advanced heart failure." | 3.69 | [Pharmacologic treatment for ventricular arrhythmias]. ( Halawa, B, 1997) |
| "Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence." | 3.68 | Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction. ( Facchin, D; Feruglio, GA; Proclemer, A; Vanuzzo, D, 1993) |
| "One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously." | 3.68 | [The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment]. ( Bellandi, F; Cantini, F; Dabizzi, RP; Palchetti, R; Pedone, T, 1993) |
| "A 65-year-old man with paroxysmal atrial flutter was treated with digoxin and flecainide." | 3.68 | 1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide. ( Ahsan, A; Aldridge, R; Bowes, R, 1993) |
| "A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation." | 3.68 | Sotalol-induced torsade de pointes: management with magnesium infusion. ( Arstall, MA; Hii, JT; Horowitz, JD; Lehman, RG, 1992) |
| "In 15 patients with recurrent ventricular tachycardia, the hemodynamic effects of amiodarone were evaluated under oral loading (1000 mg/day for 14-16 days) and during chronic treatment (600 mg/day for a further 10 weeks)." | 3.68 | Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia. ( Jung, W; Lüderitz, B; Manz, M, 1992) |
| "Intravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3." | 3.68 | Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation. ( DonMichael, TA; Ismail, Y; Nalos, PC; Nyitray, W; Pappas, JM, 1991) |
| "The long-term follow-up of 52 pts (36 M, 16 F, mean age: 62 years) with sustained ventricular tachyarrhythmias (SVT) was analyzed to assess the efficacy and feasibility of empiric amiodarone treatment." | 3.68 | [Empiric treatment with amiodarone in patients with sustained ventricular tachyarrhythmia. Results of a long-term follow-up]. ( Bonso, A; Caprioglio, F; D'Este, D; Delise, P; Di Pede, F; Gasparini, G; Piccolo, E; Raviele, A; Zanocco, A, 1990) |
| "To evaluate the efficacy and safety of long-term empiric amiodarone therapy in patients with recurrent Sustained Ventricular Tachycardia (SVT) and Chronic Chagasic Myocarditis (CCM)." | 3.68 | [Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia]. ( Bellotti, G; Lee, JH; Pileggi, F; Scanavacca, MI; Sosa, EA, 1990) |
| "Amiodarone in a low dose (200 mg/day) was administered alone or in combination with other type I antiarrhythmic drugs as a first-line agent in 33 patients with ventricular tachycardia (VT) (n = 24) or ventricular fibrillation (VF) (n = 9) secondary to coronary artery disease with healed myocardial infarction." | 3.68 | Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone. ( Kusniec, J; Mager, A; Sclarovsky, S; Strasberg, B; Zlotikamien, B, 1990) |
| "The relationship of apparent steady-state serum concentrations of amiodarone and its metabolite, desethylamiodarone, to therapeutic and toxic effects was assessed in 127 patients who had treatment-resistant ventricular or supraventricular arrhythmias or were intolerant to other agents." | 3.67 | Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. ( Belhassen, B; Greenspan, AM; Greenspon, AJ; Horowitz, LN; Rotmensch, HH; Shoshani, D; Spielman, SR; Swanson, BN; Vlasses, PH, 1984) |
| "The determinants of long-term clinical outcome were studied in 42 patients with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) who were treated with amiodarone as the sole antiarrhythmic agent." | 3.67 | Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. ( DiMarco, JP; Garan, H; Grant, G; Malacoff, RF; McGovern, B; Ruskin, JN; Sellers, TD, 1984) |
| "Verapamil is a calcium channel blocker ideally suited for the treatment of A-V nodal reciprocating supraventricular tachycardia." | 3.67 | [Idiopathic recurrent ventricular tachycardia: role of verapamil in its treatment]. ( Arriagada, C; Fajuri, A; González, R; Marchesse, M; Serrat, H, 1989) |
| "The clinical efficacy of intravenous amiodarone in terminating sustained ventricular tachycardia and in preventing recurrences of ventricular tachycardia and ventricular fibrillation was evaluated in 26 patients." | 3.67 | Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. ( Harringer, W; Herbinger, W; Kerschner, K; Leisch, F; Schützenberger, W, 1989) |
| "Amiodarone was used in 86 patients with ventricular tachycardia (VT) (67 patients) or ventricular fibrillation (19 patients) secondary to coronary artery disease." | 3.67 | Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone. ( Estes, NA; Manolis, AS; Uricchio, F, 1989) |
| "Amiodarone hydrochloride, an iodinated benzofuran derivative, is effective for treatment of supraventricular and ventricular arrhythmias." | 3.67 | Amiodarone toxicity: recurrence of interstitial pneumonitis after withdrawal of the drug. ( Morera, J; Navas, JJ; Ojanguren, I; Parra, O; Ruiz, J, 1989) |
| "Forty-two patients with a history of symptomatic ventricular tachycardia or cardiac arrest underwent electrophysiologic testing at control and early in the course of amiodarone therapy (mean 12 +/- 7 days)." | 3.67 | Amiodarone therapy: role of early and late electrophysiologic studies. ( Greenberg, RM; Greenspon, AJ; Jefferies, L; Rotmensch, HH; Volosin, KJ, 1988) |
| "The antiarrhythmic efficacy and safety of intravenous amiodarone were evaluated in 13 patients with recurrent sustained ventricular tachycardia." | 3.67 | Efficacy of intravenous amiodarone as short-term treatment for refractory ventricular tachycardia. ( Klein, RC; Machell, C; Rushforth, N; Standefur, J, 1988) |
| "Induction of ventricular tachycardia (VT) at electrophysiologic study in patients taking amiodarone poorly predicts recurrence of VT." | 3.67 | Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrop ( Chang, MS; Fineberg, N; Heger, JJ; Kammerling, JM; Klein, LS; Miles, WM; Prystowsky, EN; Zipes, DP, 1988) |
| "The relation of clinical and electrophysiologic variables to outcome was evaluated in 121 patients treated with amiodarone for sustained ventricular tachyarrhythmias." | 3.67 | Usefulness of electrophysiologic study to determine the clinical tolerance of arrhythmia recurrences during amiodarone therapy. ( Buxton, AE; Flores, B; Josephson, ME; Kadish, AH; Marchlinski, FE; Waxman, HL, 1987) |
| "Thirty-three patients with clinically recurrent ventricular tachyarrhythmias were treated with amiodarone (200 to 600 mg/day) during a mean follow-up period of 23." | 3.67 | Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment. ( Brachmann, J; Kübler, W; Rizos, I; Schmitt, C; Senges, J; Waldecker, B, 1987) |
| "The value of serial electropharmacologic testing during long-term oral amiodarone therapy for prediction of long-term drug efficacy as well as characteristics of arrhythmia recurrence is controversial." | 3.67 | Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. ( DiMarco, JP; Haines, DE; Lerman, BB; Zhu, J, 1987) |
| "Twenty-nine patients with recurrent sustained ventricular tachycardia (VT) or cardiac arrest underwent baseline, early (after 2 weeks of therapy) and late (after 5 months, mean) electrophysiologic studies during oral amiodarone therapy." | 3.67 | Amiodarone: correlation of early and late electrophysiologic studies with outcome. ( Buxton, AE; Josephson, ME; Kadish, AH; Marchlinski, FE, 1986) |
| "We examined the value of clinical variables, chronic 24-hour ambulatory ECG monitoring, and chronic electrophysiologic (EP) testing in 49 patients with recurrent and refractory sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) treated with chronic oral amiodarone in order to develop a prospective approach to the management of these patients." | 3.67 | Management of refractory sustained ventricular tachycardia with amiodarone: a reappraisal. ( Lavery, D; Saksena, S, 1987) |
| "Ventricular tachycardia induced by programmed electrical stimulation during amiodarone therapy often does not preclude a good clinical response." | 3.67 | Amiodarone: risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. ( Duncan, G; Fineberg, NS; Heger, JJ; Naccarelli, GV; Prystowsky, EN; Zipes, DP, 1985) |
| "Over a 10-year period 130 patients with drug-resistant cardiac arrhythmias associated mainly with coronary artery disease and its complications were treated with amiodarone." | 3.67 | Amiodarone for refractory cardiac arrhythmias: 10-year study. ( Eydt, JN; Leak, D, 1986) |
| "The prognostic implications of changes in ventricular ectopic activity on serial 24 hour ambulatory electrocardiographic (Holter) recordings were prospectively evaluated in 107 patients with a history of sustained ventricular tachyarrhythmias treated with amiodarone for at least 30 days." | 3.67 | Utility of ambulatory electrocardiographic monitoring for predicting recurrence of sustained ventricular tachyarrhythmias in patients receiving amiodarone. ( Brady, PM; Greenspan, AM; Horowitz, LN; Kay, HR; Rae, AP; Sokoloff, NM; Spielman, SR, 1986) |
| "The prognostic importance of electrophysiologic studies in patients with sustained ventricular tachyarrhythmias treated with amiodarone was prospectively studied in 100 consecutive patients." | 3.67 | Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. ( Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Rae, AP; Rotmensch, H; Segal, BL; Sokoloff, NM; Spielman, SR; Webb, CR, 1985) |
| "Multivariate analysis of 11 clinical variables was performed in 104 patients with sustained, symptomatic ventricular tachycardia (VT) or ventricular fibrillation treated with amiodarone to determine variables predictive of subsequent cardiac arrest or sudden death." | 3.67 | Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. ( Davis, JC; DiCarlo, LA; Evans-Bell, T; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Winston, SA, 1985) |
| "Thirteen patients with refractory, recurrent, life-threatening ventricular tachycardia (VT) underwent electrophysiologic testing before and after long-term amiodarone therapy." | 3.67 | Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. ( Griffith, LS; Platia, EV; Reid, PR; Veltri, EP, 1985) |
| "Seventy-four patients with sustained ventricular tachyarrhythmias had 22 +/- 3 hours of Holter monitoring before and after 11 +/- 6 days of amiodarone treatment." | 3.67 | Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone. ( Buxton, AE; Doherty, JU; Flores, BT; Josephson, ME; Marchlinski, FE; Waxman, HL, 1985) |
| "We tested the efficacy of intravenous amiodarone (5 mg/kg) in slowing ventricular response and/or restoring sinus rhythm in 26 patients with paroxysmal or new atrial fibrillation with fast ventricular response." | 3.67 | Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. ( Agmon, J; Arditti, A; Buimovici, B; Lewin, RF; Sclarovsky, S; Strasberg, B, 1985) |
| "Amiodarone was administered to 80 patients with recurrent cardiac tachyarrhythmias previously resistant to drug treatment." | 3.66 | Adverse reactions during treatment with amiodarone hydrochloride. ( Garan, H; Kelly, E; McGovern, B; Ruskin, JN, 1983) |
| "Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs." | 3.66 | Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. ( Bhandari, A; Keung, E; Malone, P; Morady, F; Sauve, MJ; Scheinman, MM; Schwartz, AB; Shen, EN; Sung, RJ, 1983) |
| "Twenty-three patients with sustained, recurrent, symptomatic ventricular tachycardia were treated with oral amiodarone." | 3.66 | Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. ( Girotti, LA; Kaski, JC; Messuti, H; Rosenbaum, MB; Rutitzky, B, 1981) |
| "We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation." | 3.66 | Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. ( Heger, JJ; Jackman, WM; Naccarelli, GV; Prystowsky, EN; Rinkenberger, RL; Warfel, KA; Zipes, DP, 1981) |
| "Ninety-six patients with life-threatening ventricular arrhythmias refractory to two or more conventional agents were treated with amiodarone and followed for 6 to 40 months (mean, 15 months)." | 3.66 | Amiodarone in refractory life-threatening ventricular arrhythmias. ( Cannom, DS; Feld, G; Hendrickson, J; Intarachot, V; Lopez, B; Nademanee, K; Singh, BN; Weiss, JL, 1983) |
| "Amiodarone was used in 30 patients with tachyarrhythmias refractory to treatment with several antiarrhythmic agents." | 3.66 | Amiodarone in long term management of refractory cardiac tachyarrhythmias. ( Lowe, JB; Lubbe, WF; Mercer, CJ; Roche, AH, 1981) |
| "Nine patients with life-threatening ventricular arrhythmias were administered oral amiodarone over a period of months." | 3.66 | Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. ( Finerman, WB; Hamer, AW; Mandel, WJ; Peter, T, 1981) |
| "A combined mexiletine and amiodarone treatment was applied in nine cases with recurrent refractory ventricular tachycardia." | 3.66 | Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. ( Demoulin, JC; Kulbertus, HE; Legrand, V; Mary-Rabine, L; Waleffe, A, 1980) |
| "Amiodarone hydrochloride was used to treat 19 patients with symptomatic arrhythmias refractory to quinidine sulfate, procainamide hydrochloride, disopyramide phosphate, antazoline hydrochloride, lidocaine hydrochloride, bretylium tosylate, propranolol hydrochloride, phenytoin sodium, and practotol acetanilide given to the limit of tolerance." | 3.66 | Control of refractory cardiac arrhythmias with amiodarone. ( Eydt, JN; Leak, D, 1979) |
| "Neiguan point acupuncture combined with amiodarone is superior to amiodarone alone in reducing early recurrences of patients with persistent AF after PVI." | 2.90 | Effect of acupuncture at Neiguan point combined with amiodarone therapy on early recurrence after pulmonary vein electrical isolation in patients with persistent atrial fibrillation. ( Bao, M; Dong, L; Fu, H; He, B; Huang, C; Huang, H; Liu, H; Liu, X; Liu, Y; Lu, Z; Wu, G; Yang, B; Yang, M; Yin, J; Yu, S; Zhao, Q, 2019) |
| "Amiodarone was discontinued in 18 patients randomized to amiodarone for side effects, bradycardia, or noncompliance." | 2.82 | Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial. ( Ad, N; Holmes, SD; Miller, CE; Pritchard, G; Shuman, DJ, 2016) |
| "Recurrent ventricular tachycardia among survivors of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent despite antiarrhythmic drug therapy." | 2.82 | Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. ( Blier, L; Essebag, V; Gula, L; Healey, JS; Leong-Sit, P; Nery, PB; Parkash, R; Raymond, JM; Redfearn, D; Rivard, L; Roux, JF; Sapp, JL; Sarrazin, JF; Sterns, LD; Stevenson, WG; Tang, AS; Thibault, B; Tung, SK; Veenhuyzen, GD; Wells, GA, 2016) |
| "Persistent AF and hypertension are independent risk factors for late AF recurrence after pulmonary vein isolation." | 2.79 | Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. ( Balsam, P; Kiliszek, M; Kochanowski, J; Koźluk, E; Lodziński, P; Opolski, G; Piątkowska, A; Piątkowski, R; Scisło, P, 2014) |
| "Amiodarone and diuretic treatment affected the rate of AF recurrence." | 2.75 | Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. ( Barlera, S; Cosmi, F; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lombardi, F; Maggioni, AP; Zeni, P, 2010) |
| "The primary end-point was recurrence of AF." | 2.75 | Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement. ( Cai, J; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X; Wusha, D; Xie, S, 2010) |
| "Amiodarone was employed as the anti-arrhythmic drug during the first 18 months, and diltiazem in the second half of the study." | 2.73 | Postoperative outcome of patients undergoing lung resection presenting with new-onset atrial fibrillation managed by amiodarone or diltiazem. ( Ampollini, L; Bettati, S; Bobbio, A; Caporale, D; Carbognani, P; Internullo, E; Rossini, E; Rusca, M, 2007) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Syncope was associated with increased mortality risk in SCD-HeFT regardless of treatment arm (placebo, amiodarone, or ICD)." | 2.73 | Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. ( Anderson, J; Bardy, GH; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Olshansky, B; Packer, D; Poole, JE, 2008) |
| "Amiodarone was administered as the third antiarrhythmic agent to patients who had AF recurrence on the first two antiarrhythmic agents (propafenone, sotalol or disopyramide)." | 2.71 | Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study. ( Kosior, DA; Opolski, G; Rabczenko, D; Wozakowska-Kaplon, B, 2005) |
| "Amiodarone and verapamil have been employed to treat immediate recurrences of AF (IRAF) after cardioversion." | 2.71 | Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. ( Behrens, S; Kamke, W; Stahn, A; Sticherling, C; Zabel, M, 2005) |
| "If immediate recurrences of AF occurred 2 more times, the alternative study drug was administered, and cardioversion was repeated." | 2.70 | Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation. ( Chugh, A; Greenstein, R; Hassan, S; Knight, BP; Lai, SW; Morady, F; Oral, H; Ozaydin, M; Pelosi, F; Scharf, C; Strickberger, SA; Tada, H, 2002) |
| "However, patients with no symptomatic recurrences of AF had higher scores at 3 months on measures of global well-being than those with recurrences in the first 3 months (7." | 2.70 | Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. ( Connolly, SJ; Dorian, P; Green, M; Newman, D; Paquette, M; Roy, D; Talajic, M, 2002) |
| "Twenty-five patients with persistent atrial fibrillation underwent internal defibrillation, using biphasic R wave synchronous shocks between two catheters in the high right atrium and the coronary sinus." | 2.69 | Limited internal shocks for atrial fibrillation refractory to external cardioversion. ( Adam, JF; Blommaert, D; De Roy, L; Jamart, J; Mucumbitsi, J, 1999) |
| " Thus, in these patients, the speed and dosing accuracy of an intravenous formulation would be beneficial." | 2.68 | Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. ( Cannom, DS; Chilson, DA; Friehling, T; Kopelman, HA; Kowey, PR; Levine, JH; Platia, EV; Scheinman, MM; Wilber, DJ, 1995) |
| " However, there was no clear dose-response relation observed in this trial with respect to success rates (primary end point), time to first recurrence of tachyarrhythmia (post hoc analysis) or mortality (secondary end point) over 24 h." | 2.68 | Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. ( Chilson, DA; Gomes, A; Levine, JH; Massumi, A; Platia, EV; Scheinman, MM; Winkle, RA; Woosley, RL, 1996) |
| "Treatment with amiodarone results in significant QT prolongation without altering QT dispersion." | 2.68 | Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. ( Helguera, ME; Kidwell, GA; Meierhenrich, R; Tebbe, U, 1997) |
| "Thyrotoxicosis is a common disorder, especially in women." | 2.48 | Thyrotoxicosis. ( Boelaert, K; Franklyn, JA, 2012) |
| "Incessant ventricular tachycardia and "electrical storms" are emergencies, requiring urgent action in a close cooperation between critical care physicians and cardiologists." | 2.48 | [Incessant or recurrent ventricular tachycardia. Indications for emergency ablation]. ( Figulla, HR; Kühnert, H; Prochnau, D; Surber, R, 2012) |
| "Dronedarone is an amiodarone-like benzofuran which lacks the iodine moiety and presents a methane sulfonyl group that decreases its lipophilicity, thus shortening the half-life and decreasing tissue accumulation." | 2.47 | Dronedarone. ( Caballero, R; Delpón, E; López-Farré, A; Tamargo, J, 2011) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "The most important arrhythmia is ventricular tachycardia which degenerates to ventricular fibrillation." | 2.43 | [Strategy for cardiac arrhythmias in acute coronary syndrome]. ( Sugi, K, 2006) |
| "Recurrent sustained ventricular tachycardia and ventricular fibrillation in the acute phase after cardiac surgery is the most lethal arrhythmia and may warrant acute intervention and aggressive treatment." | 2.41 | [Management of lethal ventricular arrhythmias after cardiac surgery]. ( Ohnishi, S, 2002) |
| "Patients with symptomatic ventricular tachycardia, ventricular fibrillation, or aborted sudden cardiac death remain at high risk for arrhythmia recurrence." | 2.40 | Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. ( Borggrefe, M; Breithardt, G; Eckardt, L; Haverkamp, W, 1997) |
| "Life-threatening ventricular tachyarrhythmias are the main reason for sudden cardiac death in coronary heart disease." | 2.38 | Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death. ( Eggeling, T; Hombach, V; Kochs, M, 1993) |
| "Patients with early recurrence and LVEFs ≤32% had a 1-year rate of mortality or HTx of 55%." | 1.72 | Clinical Outcomes in Patients With Dilated Cardiomyopathy and Ventricular Tachycardia. ( Arya, A; Baldinger, SH; Berruezo, A; Carbucicchio, C; Catto, V; de Riva, M; Deneke, T; Ebert, M; Gaspar, T; Hindricks, G; Kumar, S; Piorkowski, C; Shivkumar, K; Soejima, K; Stevenson, WG; Tedrow, UB; van Rein, N; Vaseghi, M; Wijnmaalen, AP; Zeppenfeld, K, 2022) |
| "51 ± 38." | 1.62 | Frontal plane QRS-T angle predicts early recurrence of acute atrial fibrillation after successful pharmacological cardioversion with intravenous amiodarone. ( Celik, A; Eyuboglu, M, 2021) |
| "Cardiac lipomas are rare benign heart tumors." | 1.56 | Ventricular tachycardia: beginning and ending fate of a benign invasive cardiac lipoma. ( Ahmed, MM; Aladmawi, M; Alamro, B; ALsanei, A; AlSomali, A; Echahidi, NM; Fawzy, N; Kharabsheha, S; Vriz, O, 2020) |
| "Secondary endpoints comprised ES recurrences, rehospitalization, and major adverse cardiac events (MACE) at 4 years." | 1.51 | Impact of Different Pharmacotherapies on Long-Term Outcomes in Patients with Electrical Storm. ( Akin, I; Akin, M; Behnes, M; Bertsch, T; Bollow, A; Borggrefe, M; Ellguth, D; Engelke, N; Kim, SH; Mashayekhi, K; Müller, J; Nienaber, C; Reichelt, T; Reiser, L; Schupp, T; Taton, G, 2019) |
| "Polymorphic ventricular tachycardia (VT) without QT prolongation is well described in patients without structural heart disease (mainly idiopathic ventricular fibrillation and Brugada syndrome) and in patients with acute ST-elevation myocardial infarction." | 1.51 | Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. ( Amit, G; Asher, E; Belhassen, B; Chorin, E; Halkin, A; Havakuk, O; Hochstadt, A; Laish-Farkash, A; Lee, JK; Rosso, R; Tovia-Brodie, O; Viskin, D; Viskin, S, 2019) |
| "However, late recurrences are more common compared to paroxAF." | 1.51 | Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy. ( Benák, A; Bencsik, G; Herczeg, A; Kohári, M; Makai, A; Pap, R; Sághy, L, 2019) |
| "VT recurrence was higher for >1RFA vs 1RFA (29% vs 24%, P <." | 1.46 | Outcomes after repeat ablation of ventricular tachycardia in structural heart disease: An analysis from the International VT Ablation Center Collaborative Group. ( Bunch, TJ; Burkhardt, JD; Callans, DJ; Della Bella, P; Di Biase, L; Dickfeld, T; Frankel, DS; Lakkireddy, D; Marchlinski, FE; Mathuria, N; Nakahara, S; Natale, A; Santangeli, P; Sauer, WH; Shivkumar, K; Stevenson, WG; Tedrow, U; Tholakanahalli, VN; Tung, R; Tzou, WS; Vakil, K; Vaseghi, M; Vergara, P; Vunnam, R; Weiss, JP, 2017) |
| "Bepridil reduced the recurrence of AF compared with AMD and SCB in patients who underwent catheter ablation for persistent AF." | 1.43 | Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation. ( Iitsuka, K; Kato, M; Kondo, T; Miake, J; Ogura, K; Yamamoto, K, 2016) |
| "Dronedarone is a benzofuran derivative resembling amiodarone that was intended to reduce the iodine-associated tissue deposition and organ toxicity seen with the latter." | 1.43 | The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature. ( Brent Mitchell, L; Kuriachan, V; Rizkallah, J, 2016) |
| "Perinatal atrial flutter is a serious arrhythmia." | 1.42 | [Repeated electrical cardioversions and amiodarone for recurrent neonatal atrial flutter]. ( Crochelet, AS; Jacquemart, C; Massin, M, 2015) |
| "The total AF recurrence rate was 67% and lone AF was significantly more often associated with AF recurrences than non-lone AF (84% vs." | 1.39 | Which patient is most likely to benefit from dronedarone? Analysis from the Magdeburg Dronedarone Registry (MADRE study). ( Braun-Dullaeus, RC; Esperer, HD; Genz, C; Kluba, K; Rauwolf, T; Said, SM; Schmeisser, A, 2013) |
| "For AF recurrence; duration of AF, left atrial (LA) diameter, maximum LA volume index, mitral A velocity and LA lateral AEMD were significant parameters in univariate-analysis, however LA lateral AEMD was the only significant parameter in multivariate-analysis (OR: 1." | 1.39 | Predictive value of atrial electromechanical delay for atrial fibrillation recurrence. ( Akkaya, M; Ari, H; Ari, S; Aydin, C; Bozat, T; Çetinkaya, S; Emlek, N; Karaağaç, K; Melek, M; Sarigül, OY; Şentürk, M; Yilmaz, M, 2013) |
| "Adenosine has been well studied as a mainstay treatment, but the methods of adenosine administration have not been very well delineated." | 1.38 | Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia. ( Goodman, IS; Lu, CJ, 2012) |
| "The average time to recurrence of AF after RFCA was 9." | 1.38 | Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. ( Ban, JE; Choi, JI; Kang, JH; Kim, MN; Kim, S; Kim, YH; Lee, DI; Lim, HE; Park, SW; Park, YM, 2012) |
| "During a 4-week follow-up, AF recurrence was observed in 41 patients (65." | 1.37 | Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion. ( Alcaraz, R; Hornero, F; Rieta, JJ, 2011) |
| "The strongest factor associated with AF recurrence was hsCRP at 48 h > or =2." | 1.36 | Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. ( Dragomanovits, S; Faviou, E; Kalogeropoulos, AS; Kremastinos, DT; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2010) |
| "Time to persistent arrhythmia recurrence was compared between first and multiple DCCV, and the effect of age, gender, presence of heart disease, left atrial size, fractional shortening, arrhythmia duration, anti-arrhythmic drug therapy (AAD) and other concomitant cardiac medication was evaluated using the Kaplan-Meier method and Cox's Proportional-hazards model." | 1.36 | First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes. ( Arya, A; Boodhoo, L; Bordoli, G; Cheek, E; Large, J; Lloyd, GW; Mitchell, A; Patel, NR; Pugh, P; Silberbauer, JS; Sulke, AN; Taggu, W; Vrahimides, J, 2010) |
| "Two hundred forty patients with lone paroxysmal atrial fibrillation were assigned to four groups." | 1.35 | The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study. ( Chen, Y; Du, H; Lan, X; Ling, Z; Liu, Z; She, Q; Su, L; Wu, J; Yin, Y, 2008) |
| "Transient hypothyroidism was observed in only two patients (5%) with AIH, though was not observed in TMNG." | 1.35 | Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). ( Bartkowiak, Z; Czarnywojtek, A; Czepczynski, R; Florek, E; Ruchala, M; Sowinski, J; Szczepanek, E; Wasko, R; Zamyslowska, H; Zgorzalewicz-Stachowiak, M, 2009) |
| "Amiodarone is a lipophilic drug that concentrates in the liver and usually, over a period of time, leads to toxicity related to drug accumulation." | 1.35 | Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. ( Chang, C; Fiel, MI; Raja, K; Thung, SN, 2009) |
| "Recurrent life-threatening episodes of ventricular tachycardia persisted despite maximal antiarrhythmic theraphy with amiodarone, metoprolol and mexiletine." | 1.33 | Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone. ( Anastasiou-Nana, MI; Kanakakis, J; Rokas, S; Tsagalou, EP, 2005) |
| "Average time for recurrence of FEA positive patients (4." | 1.33 | Spectral turbulence analysis of the signal-averaged electrocardiogram of the atrial activation as predictor of recurrence of idiopathic and persistent atrial fibrillation. ( Barbosa, EC; Benchimol Barbosa, PR; de Souza Bomfim, A; Destro, C; Ginefra, P; Helena Cardoso Boghossian, S; Nadal, J, 2006) |
| "The selective ablation of the recurrent ventricular tachycardia (VT) in a 75-year old patient after extensive inferior myocardial infarction (24 years ago), with low ejection fraction was performed." | 1.33 | [Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation]. ( Chojnowska, L; Derejko, P; Grzybowski, J; Iwanek, M; Kepski, R; Przybylski, A; Szumowski, Ł; Szwed, H; Urbanek, P; Walczak, F, 2006) |
| "Amiodarone treatment was terminated, and the patient was given corticosteroids." | 1.33 | Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. ( Kobayashi, N; Kojima, J; Kudo, K; Okayasu, K; Sugiyama, H; Takeda, Y; Yoshizawa, A, 2006) |
| "High recurrence rate is still a major problem associated with ablation of paroxysmal atrial fibrillation (AF)." | 1.32 | Clinical outcome of very late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. ( Chan, P; Chang, MS; Chen, SA; Ding, YA; Hsieh, MH; Huang, JL; Lin, WS; Lin, YK; Tai, CT; Tsai, CF; Tsao, HM; Ueng, KC; Yu, WC, 2003) |
| "During follow-up a recurrence rate of 33% was observed in Group 1 (6 recurrences in 18 patients; p < 0." | 1.32 | Previous therapy with amiodarone increases the recurrence rate in successfully ablated patients with isthmus-dependent atrial flutter. ( Elvas, L; Providência, L; Ventura, M, 2004) |
| "Patients for whom recurrent ventricular tachycardia and fibrillation are suppressed with intravenous amiodarone and who are discharged receiving oral amiodarone have an 80% 1-year survival rate." | 1.31 | Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias. ( Fineberg, N; Fogel, RI; Herre, JM; Kopelman, HA; Kowey, PR; Prystowsky, EN; Trohman, RG, 2000) |
| "Average follow up at first AF recurrence was 18." | 1.31 | Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002) |
| "Recurrence is common, although antiarrhythmic drugs often effectively decrease the number and duration of recurrent AF episodes." | 1.30 | Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. ( Duytschaever, M; Haerynck, F; Jordaens, L; Tavernier, R, 1998) |
| " However, in this patient, effective control of the arrhythmia was achieved with a moderate dosage of oral amiodarone (600 mg daily for 4 weeks, then 400 mg daily), and he had no further episodes of presyncope." | 1.30 | Amiodarone for control of recurrent ventricular tachycardia secondary to cardiac metastasis. ( Leak, D, 1998) |
| "Amiodarone was used as first line therapy or after failure of digoxin." | 1.30 | [Recommendations for the treatment of recurrent supraventricular tachycardia in infants]. ( Acar, P; Aggoun, Y; Bonnet, D; Kachaner, J; Sidi, D; Villain, E, 1998) |
| "Early recurrence of atrial fibrillation (AF) has been reported to occur in a significant number of patients after internal cardioversion." | 1.30 | Early recurrence of atrial fibrillation after external cardioversion. ( Chang, MS; Chen, CC; Chen, SA; Ding, YA; Hsieh, MH; Hsu, TL; Lin, YK; Tai, CT; Tsai, CF; Yu, WC, 1999) |
| "Amiodarone is a powerful suppressant of VPCs, but Holter suppression of this ectopic activity is not predictive of clinical outcome." | 1.29 | Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease. ( Doyle, TK; Nasir, N; Pacifico, A; Wheeler, SH, 1994) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 1.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Surprisingly, arrhythmia recurrence rates were not significantly different by the method of determining an efficacy prediction." | 1.29 | Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management. ( Anderson, JL, 1995) |
| "Prevention of recurrence with oral amiodarone was effective in all cases but was responsible for secondary effects in 4 cases." | 1.29 | [Late supraventricular arrhythmia complicating Fontan or cavopulmonary type procedures. Apropos of 7 cases]. ( David, N; Foucault, JP; Iselin, M; Maragnès, P; Villain, E, 1996) |
| "Celiprolol is a cardioselective beta-blocker with a partial beta-2 agonist activity and an alpha-2 blocking activity, with a minimal depressant effect on heart rate." | 1.29 | [Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia]. ( Coutte, R; Frank, R; Hidden, F; Himbert, C; Naditch, L; Tonet, J, 1996) |
| "Amiodarone was prescribed orally at degressive doses." | 1.29 | [Predictive factors of induction of ventricular arrhythmia under amiodarone]. ( Bellon, C; Bonnefoy, E; Bouchayer, D; Bourret, N; Chevalier, P; Kirkorian, G; Richalet, C; Touboul, P, 1996) |
| " The mean maintenance dosage was 7." | 1.28 | Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. ( Garson, A; Guccione, P; Paul, T, 1990) |
| "Amiodarone therapy was associated with maintenance of sinus rhythm, fewer alterations in drug therapy, fewer embolic episodes and fewer attempted direct current cardioversions (during a shorter follow-up period)." | 1.28 | Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. ( Frenneaux, MP; Karatasakis, G; McKenna, WJ; Poloniecki, JD; Robinson, K; Stockins, B, 1990) |
| "A patient with preexistent left bundle branch block and spontaneous ventricular tachycardia based upon the bundle branch reentry mechanism underwent electrophysiological testing for the evaluation of sotalol drug efficacy." | 1.28 | Inadvertent catheter-induced right bundle branch block in a patient with preexistent left bundle branch block and recurrent macroreentrant ventricular tachycardia. ( Gössinger, HD; Leitha, T; Mösslacher, H; Siostrzonek, P; Wagner, L, 1989) |
| "Amiodarone was discontinued because of side effects in 14%, 26% and 37% of patients after 1, 3 and 5 years, respectively." | 1.28 | Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. ( Goldberg, H; Griffin, JC; Helmy, I; Herre, JM; Langberg, JJ; Malone, P; Sauve, MJ; Scheinman, MM, 1989) |
| "TWelve patients had overt congestive heart failure." | 1.27 | Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia. ( DiCarlo, L; Morady, F; Scheinman, MM; Shapiro, W; Shen, E; Sung, RJ, 1983) |
| "To our knowledge, this recurrence of amiodarone pulmonary toxicity has not been reported previously." | 1.27 | Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy. ( Cole, S; Conway, M; Joelson, J; Kluger, J, 1984) |
| "Amiodarone was used in the treatment of 21 patients with supraventricular or ventricular arrhythmias which were refractory to conventional antiarrhythmic drugs, individually or in combination." | 1.27 | Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias. ( Best, JF; Dunn, M; Lynch, L; Rinkenberger, R, 1986) |
| "Amiodarone was administered in a loading dose of 1." | 1.27 | Treatment of ventricular arrhythmia after corrective cardiac surgery in a neonate with intravenous amiodarone. ( Bogers, AJ; Huysmans, HA; Ottenkamp, J; Quaegebeur, JM, 1987) |
| "Flecainide was administered to other patients during spontaneous episodes of tachyarrhythmias." | 1.27 | [Treatment of recurrent supraventricular tachyarrhythmias with flecainide or a flecainide and amiodarone combination]. ( Capestro, F; Ciampani, N; Costantini, C; Fratadocchi, GB; Mazzanti, M; Molini, E; Purcaro, A, 1987) |
| "Amiodarone has been reported to be a remarkably safe and effective drug in the European and South American experience but American investigators have published conflicting data." | 1.27 | Safety and efficacy of amiodarone. The low-dose perspective. ( Friehling, TD; Kowey, PR; Marinchak, RA; Stohler, JL; Sulpizi, AM, 1988) |
| " Sixty-three patients (55%) had one or more adverse effects attributed to amiodarone." | 1.27 | Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. ( DiMarco, JP; Greenberg, ML; Kaiser, DL; Lerman, BB; Shipe, JR, 1987) |
| "The actuarial risk for sudden death in group B was 31% (95% confidence interval, 11% to 51%) at 1 and 2 years, a value that was significantly higher than that for group A (p less than 0." | 1.27 | The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias. ( Elson, JJ; Fiedler, SB; Fogoros, RN, 1987) |
| "An unusual case of recurrence of amiodarone pulmonary toxicity is described." | 1.27 | [Recurrent alveolitis caused by amiodarone]. ( Ciani, F; Padrini, R; Pandullo, C; Pivotti, F; Scardi, S, 1986) |
| " In 17 of the 29 pts not controlled by this regimen, the dosage of A was increased to 6000-8000 mg week-1; short-term control of VT was achieved in 9/17 (53%) pts, but over a long-term follow-up 5/9 (56%) died and severe side-effects (11% pulmonary fibrosis and 11% hepatitis) occurred in 22%." | 1.27 | Medical and surgical treatment of sustained and recurrent post-infarction ventricular tachycardia. ( Bobba, P; Bressan, MA; Chimienti, M; Martinelli, L; Montemartini, C; Pagnin, A; Previtali, M; Salerno, JA; Vigano, M, 1985) |
| "When amiodarone was stopped in nine patients, the changes in QTc, T4 and rT3 regressed toward normal and arrhythmia recurred in eight 2-20 weeks (mean 7." | 1.26 | Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ( Hendrickson, JA; Hershman, J; Melmed, S; Nademanee, K; Reed, AW; Singh, BN, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (24.53) | 18.7374 |
| 1990's | 86 (27.04) | 18.2507 |
| 2000's | 78 (24.53) | 29.6817 |
| 2010's | 63 (19.81) | 24.3611 |
| 2020's | 13 (4.09) | 2.80 |
| Authors | Studies |
|---|---|
| Eyuboglu, M | 1 |
| Celik, A | 1 |
| Lam, JC | 1 |
| Stevenson, B | 1 |
| Lee, YG | 1 |
| Maurer, J | 1 |
| Patanwala, AE | 1 |
| Radosevich, JJ | 1 |
| Zeppenfeld, K | 1 |
| Wijnmaalen, AP | 1 |
| Ebert, M | 1 |
| Baldinger, SH | 1 |
| Berruezo, A | 1 |
| Catto, V | 1 |
| Vaseghi, M | 2 |
| Arya, A | 2 |
| Kumar, S | 3 |
| de Riva, M | 1 |
| Deneke, T | 1 |
| Gaspar, T | 1 |
| Soejima, K | 1 |
| van Rein, N | 1 |
| Tedrow, UB | 1 |
| Piorkowski, C | 1 |
| Shivkumar, K | 2 |
| Carbucicchio, C | 1 |
| Hindricks, G | 2 |
| Stevenson, WG | 6 |
| Bennett, RG | 1 |
| Garikapati, K | 1 |
| Campbell, TG | 1 |
| Kotake, Y | 2 |
| Turnbull, S | 1 |
| Bhaskaran, A | 1 |
| De Silva, K | 1 |
| Kanawati, J | 1 |
| Zhou, J | 1 |
| Wong, MS | 1 |
| Arunachalam, K | 1 |
| Maan, A | 1 |
| Chu, A | 1 |
| Alegret, JM | 1 |
| Viñolas, X | 1 |
| Tajes, H | 1 |
| Valdovinos, P | 1 |
| Palomares, R | 1 |
| Arias, MA | 2 |
| Bazán, V | 1 |
| Pachón, M | 1 |
| Loughlin, G | 1 |
| Naccarelli, GV | 3 |
| Bhatt, DL | 1 |
| Camm, AJ | 1 |
| Le Heuzey, JY | 3 |
| Lombardi, F | 2 |
| Tamargo, J | 2 |
| Martinez, JM | 1 |
| Naditch-Brûlé, L | 1 |
| Vriz, O | 1 |
| Ahmed, MM | 1 |
| Kharabsheha, S | 1 |
| Aladmawi, M | 1 |
| Alamro, B | 1 |
| AlSomali, A | 1 |
| Fawzy, N | 1 |
| ALsanei, A | 1 |
| Echahidi, NM | 1 |
| Huang, R | 1 |
| Lin, J | 1 |
| Gong, K | 1 |
| Chen, L | 1 |
| Fan, L | 1 |
| Zhang, F | 1 |
| Zhang, Y | 2 |
| Chen, X | 4 |
| Xu, Z | 1 |
| Schupp, T | 2 |
| Behnes, M | 2 |
| Kim, SH | 2 |
| Müller, J | 2 |
| Weidner, K | 1 |
| Reiser, L | 2 |
| Huseynov, A | 1 |
| Bollow, A | 2 |
| Borggrefe, M | 4 |
| Taton, G | 2 |
| Reichelt, T | 2 |
| Ellguth, D | 2 |
| Engelke, N | 2 |
| Akin, M | 2 |
| Große Meininghaus, D | 1 |
| Bertsch, T | 2 |
| Akin, I | 2 |
| Tan, Y | 1 |
| Sia, P | 1 |
| Simon, S | 1 |
| Di Biase, L | 3 |
| Romero, J | 1 |
| Du, X | 1 |
| Mohanty, S | 2 |
| Trivedi, C | 2 |
| Della Rocca, DG | 1 |
| Patel, K | 1 |
| Sanchez, J | 2 |
| Yang, R | 1 |
| Alviz, I | 1 |
| Mohanty, P | 2 |
| Gianni, C | 1 |
| Tarantino, N | 1 |
| Zhang, XD | 1 |
| Horton, R | 2 |
| Al-Ahmad, A | 2 |
| Lakkireddy, D | 3 |
| Burkhardt, DJ | 1 |
| Chen, M | 1 |
| Natale, A | 3 |
| Kettering, K | 1 |
| Gramley, F | 1 |
| Tzou, WS | 1 |
| Tung, R | 1 |
| Frankel, DS | 1 |
| Santangeli, P | 2 |
| Bunch, TJ | 1 |
| Weiss, JP | 1 |
| Tholakanahalli, VN | 1 |
| Vunnam, R | 1 |
| Dickfeld, T | 1 |
| Mathuria, N | 1 |
| Tedrow, U | 1 |
| Vergara, P | 1 |
| Vakil, K | 1 |
| Nakahara, S | 1 |
| Burkhardt, JD | 2 |
| Callans, DJ | 1 |
| Della Bella, P | 1 |
| Marchlinski, FE | 4 |
| Sauer, WH | 1 |
| Darkner, S | 3 |
| Goetze, JP | 1 |
| Henningsen, K | 1 |
| Pehrson, S | 3 |
| Svendsen, JH | 3 |
| Kavakli, AS | 1 |
| Kavrut Ozturk, N | 1 |
| Fong, HK | 1 |
| Abdullah, O | 1 |
| Gautam, S | 1 |
| Münkler, P | 1 |
| Wutzler, A | 1 |
| Attanasio, P | 1 |
| Huemer, M | 1 |
| Parwani, AS | 1 |
| Haverkamp, W | 3 |
| Meyer, C | 1 |
| Boldt, LH | 1 |
| Maqdasy, S | 2 |
| Benichou, T | 1 |
| Dallel, S | 1 |
| Roche, B | 2 |
| Desbiez, F | 2 |
| Montanier, N | 1 |
| Batisse-Lignier, M | 2 |
| Tauveron, I | 2 |
| Nienaber, C | 1 |
| Mashayekhi, K | 1 |
| Viskin, S | 1 |
| Chorin, E | 1 |
| Viskin, D | 1 |
| Hochstadt, A | 1 |
| Halkin, A | 1 |
| Tovia-Brodie, O | 1 |
| Lee, JK | 3 |
| Asher, E | 1 |
| Laish-Farkash, A | 1 |
| Amit, G | 1 |
| Havakuk, O | 1 |
| Belhassen, B | 4 |
| Rosso, R | 1 |
| Benák, A | 1 |
| Kohári, M | 1 |
| Herczeg, A | 1 |
| Makai, A | 1 |
| Bencsik, G | 1 |
| Sághy, L | 1 |
| Pap, R | 1 |
| Diederichsen, SZ | 1 |
| Johannessen, A | 2 |
| Hansen, J | 2 |
| Yin, J | 1 |
| Yang, M | 1 |
| Yu, S | 1 |
| Fu, H | 1 |
| Huang, H | 1 |
| Yang, B | 1 |
| Liu, Y | 1 |
| He, B | 1 |
| Bao, M | 1 |
| Wu, G | 1 |
| Lu, Z | 1 |
| Liu, H | 1 |
| Liu, X | 1 |
| Dong, L | 1 |
| Huang, C | 1 |
| Zhao, Q | 1 |
| Arnouk, S | 1 |
| Aberle, C | 1 |
| Altshuler, D | 1 |
| Merchan, C | 1 |
| Piper, GL | 1 |
| Papadopoulos, J | 1 |
| Dagres, N | 1 |
| Lewalter, T | 2 |
| Lip, GY | 1 |
| Pison, L | 1 |
| Proclemer, A | 4 |
| Blomström-Lundqvist, C | 1 |
| Mikhaylov, EN | 1 |
| Orshanskaya, VS | 1 |
| Lebedev, AD | 1 |
| Szili-Torok, T | 1 |
| Lebedev, DS | 1 |
| Said, SM | 1 |
| Esperer, HD | 1 |
| Kluba, K | 1 |
| Genz, C | 1 |
| Rauwolf, T | 1 |
| Schmeisser, A | 1 |
| Braun-Dullaeus, RC | 1 |
| Spina, R | 1 |
| Granger, E | 1 |
| Walker, B | 1 |
| Subbiah, RN | 1 |
| Lodziński, P | 1 |
| Kiliszek, M | 1 |
| Koźluk, E | 1 |
| Piątkowska, A | 1 |
| Balsam, P | 1 |
| Kochanowski, J | 1 |
| Scisło, P | 1 |
| Piątkowski, R | 1 |
| Opolski, G | 3 |
| Galperin, J | 2 |
| Elizari, MV | 2 |
| Bonato, R | 2 |
| Ledesma, R | 2 |
| Vazquez Blanco, M | 1 |
| Lago, M | 2 |
| Spada, P | 1 |
| Piasentin, J | 1 |
| Chiale, PA | 2 |
| Ari, H | 1 |
| Ari, S | 1 |
| Akkaya, M | 1 |
| Aydin, C | 1 |
| Emlek, N | 1 |
| Sarigül, OY | 1 |
| Çetinkaya, S | 1 |
| Bozat, T | 1 |
| Şentürk, M | 1 |
| Karaağaç, K | 1 |
| Melek, M | 1 |
| Yilmaz, M | 1 |
| Karavelioğlu, Y | 1 |
| Karapınar, H | 1 |
| Yüksel, M | 1 |
| Memiç, K | 1 |
| Sarak, T | 1 |
| Kurt, R | 1 |
| Yilmaz, A | 1 |
| Iannone, P | 1 |
| Haupt, E | 1 |
| Flego, G | 1 |
| Truglio, P | 1 |
| Minardi, M | 1 |
| Clarke, S | 1 |
| Magrini, N | 1 |
| Osawa, H | 1 |
| Muraki, S | 1 |
| Sakurada, T | 1 |
| Kawaharada, N | 1 |
| Sasaki, J | 1 |
| Araki, E | 1 |
| Nakashima, S | 1 |
| Chun, KJ | 1 |
| Byeon, K | 1 |
| Im, SI | 1 |
| Park, KM | 1 |
| Park, SJ | 1 |
| Kim, JS | 1 |
| On, YK | 1 |
| Nielsen, JB | 1 |
| Loewe, A | 1 |
| Lutz, Y | 1 |
| Wilhelms, M | 1 |
| Sinnecker, D | 1 |
| Barthel, P | 1 |
| Scholz, EP | 1 |
| Dössel, O | 1 |
| Schmidt, G | 1 |
| Seemann, G | 1 |
| Bai, R | 1 |
| Gallinghouse, JG | 1 |
| Sanchez, JE | 1 |
| Hranitzky, PM | 1 |
| Zagrodzky, J | 1 |
| Pelargonio, G | 1 |
| Reddy, M | 1 |
| Forleo, G | 1 |
| Rossillo, A | 1 |
| Themistoclakis, S | 2 |
| Hongo, R | 1 |
| Beheiry, S | 1 |
| Casella, M | 1 |
| Dello Russo, A | 1 |
| Tondo, C | 1 |
| Kurita, T | 4 |
| Akaiwa, Y | 1 |
| Yasuoka, R | 1 |
| Motoki, K | 1 |
| Kobuke, K | 1 |
| Iwanaga, Y | 1 |
| Miyazaki, S | 1 |
| Guerra, F | 1 |
| Hohnloser, SH | 2 |
| Kowey, PR | 5 |
| Crijns, HJ | 5 |
| Aliot, EM | 1 |
| Radzik, D | 2 |
| Roy, D | 3 |
| Connolly, S | 2 |
| Capucci, A | 3 |
| Crochelet, AS | 1 |
| Jacquemart, C | 1 |
| Massin, M | 1 |
| Qin, D | 1 |
| Leef, G | 1 |
| Alam, MB | 1 |
| Rattan, R | 1 |
| Munir, MB | 1 |
| Patel, D | 1 |
| Khattak, F | 1 |
| Adelstein, E | 1 |
| Jain, SK | 1 |
| Saba, S | 1 |
| Ad, N | 1 |
| Holmes, SD | 1 |
| Shuman, DJ | 1 |
| Pritchard, G | 1 |
| Miller, CE | 1 |
| Kondo, T | 1 |
| Miake, J | 1 |
| Kato, M | 1 |
| Ogura, K | 1 |
| Iitsuka, K | 1 |
| Yamamoto, K | 1 |
| Auclair, C | 1 |
| Citron, B | 1 |
| Thieblot, P | 1 |
| Lusson, JR | 1 |
| Mitrić, G | 1 |
| Udy, A | 1 |
| Bandeshe, H | 1 |
| Clement, P | 1 |
| Boots, R | 1 |
| Sapp, JL | 1 |
| Wells, GA | 1 |
| Parkash, R | 1 |
| Blier, L | 1 |
| Sarrazin, JF | 1 |
| Thibault, B | 1 |
| Rivard, L | 1 |
| Gula, L | 1 |
| Leong-Sit, P | 1 |
| Essebag, V | 1 |
| Nery, PB | 1 |
| Tung, SK | 1 |
| Raymond, JM | 1 |
| Sterns, LD | 1 |
| Veenhuyzen, GD | 1 |
| Healey, JS | 1 |
| Redfearn, D | 1 |
| Roux, JF | 1 |
| Tang, AS | 1 |
| Rizkallah, J | 1 |
| Kuriachan, V | 1 |
| Brent Mitchell, L | 1 |
| White, CM | 1 |
| Nguyen, E | 1 |
| Liu, Z | 1 |
| Ling, Z | 1 |
| Su, L | 1 |
| Wu, J | 1 |
| Lan, X | 1 |
| Chen, Y | 1 |
| Du, H | 1 |
| She, Q | 1 |
| Yin, Y | 1 |
| Stanaitiene, G | 1 |
| Babarskiene, RM | 1 |
| Marwick, PC | 1 |
| Levin, AI | 1 |
| Coetzee, AR | 1 |
| Czarnywojtek, A | 1 |
| Czepczynski, R | 1 |
| Ruchala, M | 1 |
| Wasko, R | 1 |
| Zgorzalewicz-Stachowiak, M | 1 |
| Szczepanek, E | 1 |
| Zamyslowska, H | 1 |
| Bartkowiak, Z | 1 |
| Florek, E | 1 |
| Sowinski, J | 1 |
| Shimada, YJ | 1 |
| Sato, K | 2 |
| Hanon, S | 1 |
| Schweitzer, P | 1 |
| Raja, K | 1 |
| Thung, SN | 1 |
| Fiel, MI | 1 |
| Chang, C | 1 |
| Rizos, I | 2 |
| Rigopoulos, AG | 1 |
| Kalogeropoulos, AS | 1 |
| Tsiodras, S | 1 |
| Dragomanovits, S | 1 |
| Sakadakis, EA | 1 |
| Faviou, E | 1 |
| Kremastinos, DT | 2 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| Disertori, M | 1 |
| Barlera, S | 1 |
| Latini, R | 1 |
| Maggioni, AP | 1 |
| Zeni, P | 1 |
| Di Pasquale, G | 1 |
| Cosmi, F | 1 |
| Franzosi, MG | 1 |
| Pires, LM | 1 |
| Leiria, TL | 1 |
| de Lima, GG | 1 |
| Kruse, ML | 1 |
| Nesralla, IA | 1 |
| Kalil, RA | 1 |
| Silberbauer, JS | 1 |
| Vrahimides, J | 1 |
| Cheek, E | 1 |
| Mitchell, A | 1 |
| Boodhoo, L | 1 |
| Pugh, P | 1 |
| Large, J | 1 |
| Bordoli, G | 1 |
| Taggu, W | 1 |
| Lloyd, GW | 1 |
| Patel, NR | 1 |
| Sulke, AN | 1 |
| Ji, Q | 1 |
| Mei, Y | 1 |
| Wang, X | 1 |
| Feng, J | 1 |
| Wusha, D | 1 |
| Cai, J | 1 |
| Sun, Y | 1 |
| Xie, S | 1 |
| Zhang, P | 1 |
| Mu, Y | 1 |
| Gao, M | 1 |
| Wang, JR | 1 |
| Wang, Y | 1 |
| Su, LQ | 1 |
| Hou, YL | 1 |
| Lopez, KN | 1 |
| Decker, JA | 1 |
| Friedman, RA | 1 |
| Kim, JJ | 1 |
| Wann, LS | 2 |
| Curtis, AB | 3 |
| January, CT | 1 |
| Ellenbogen, KA | 2 |
| Lowe, JE | 2 |
| Estes, NA | 2 |
| Page, RL | 1 |
| Ezekowitz, MD | 1 |
| Slotwiner, DJ | 1 |
| Jackman, WM | 2 |
| Tracy, CM | 1 |
| Fuster, V | 1 |
| Rydén, LE | 1 |
| Cannom, DS | 3 |
| Olsson, S | 1 |
| Prystowsky, EN | 7 |
| Halperin, JL | 2 |
| Tamargo, JL | 1 |
| Kay, GN | 1 |
| Jacobs, AK | 1 |
| Anderson, JL | 2 |
| Albert, N | 1 |
| Hochman, JS | 1 |
| Buller, CE | 1 |
| Kushner, FG | 1 |
| Creager, MA | 1 |
| Ohman, EM | 1 |
| Ettinger, SM | 1 |
| Guyton, RA | 1 |
| Tarkington, LG | 1 |
| Yancy, CW | 1 |
| Saliba, W | 1 |
| Wazni, OM | 1 |
| Werner, CR | 1 |
| Riessen, R | 1 |
| Gregor, M | 1 |
| Bitzer, M | 1 |
| Lunati, M | 1 |
| Pedretti, S | 1 |
| López-Farré, A | 1 |
| Caballero, R | 1 |
| Delpón, E | 1 |
| Alcaraz, R | 1 |
| Hornero, F | 1 |
| Rieta, JJ | 1 |
| Huang, JH | 1 |
| Lin, YK | 3 |
| Hsieh, MH | 3 |
| Chen, SA | 4 |
| Chen, YJ | 1 |
| Eskes, SA | 1 |
| Endert, E | 1 |
| Fliers, E | 1 |
| Geskus, RB | 1 |
| Dullaart, RP | 1 |
| Links, TP | 1 |
| Wiersinga, WM | 1 |
| Goodman, IS | 1 |
| Lu, CJ | 1 |
| Franklyn, JA | 1 |
| Boelaert, K | 1 |
| Menzorov, MV | 1 |
| Shutov, AM | 1 |
| Serov, VA | 1 |
| Jindal, G | 1 |
| Singh, S | 1 |
| Suri, D | 1 |
| Rawat, A | 1 |
| Rohit, M | 1 |
| Surber, R | 1 |
| Prochnau, D | 1 |
| Kühnert, H | 1 |
| Figulla, HR | 1 |
| Meinertz, T | 2 |
| Kang, JH | 1 |
| Lee, DI | 1 |
| Kim, S | 1 |
| Kim, MN | 1 |
| Park, YM | 1 |
| Ban, JE | 1 |
| Choi, JI | 1 |
| Lim, HE | 1 |
| Park, SW | 1 |
| Kim, YH | 1 |
| Hein, W | 1 |
| Ellringmann, U | 1 |
| Vollmann, D | 1 |
| Rostock, T | 2 |
| Schott, P | 1 |
| Immordino, L | 1 |
| Crijns, H | 1 |
| Aliot, E | 1 |
| Hohnloser, S | 1 |
| Kowey, P | 1 |
| Madrid, AH | 1 |
| Bueno, MG | 1 |
| Rebollo, JM | 1 |
| Marín, I | 1 |
| Peña, G | 1 |
| Bernal, E | 1 |
| Rodriguez, A | 1 |
| Cano, L | 1 |
| Cano, JM | 1 |
| Cabeza, P | 1 |
| Moro, C | 1 |
| Ohnishi, S | 1 |
| Oral, H | 2 |
| Ozaydin, M | 1 |
| Tada, H | 2 |
| Chugh, A | 2 |
| Hassan, S | 1 |
| Scharf, C | 2 |
| Lai, SW | 1 |
| Greenstein, R | 1 |
| Pelosi, F | 2 |
| Knight, BP | 1 |
| Strickberger, SA | 1 |
| Morady, F | 5 |
| Sharp, JC | 1 |
| Whalley, DW | 1 |
| Kapoor, A | 1 |
| Singh, RK | 1 |
| Pandey, CM | 1 |
| Sinha, N | 1 |
| Ouarda, F | 1 |
| M'Saad, H | 1 |
| Chaker, L | 1 |
| Hakim, K | 1 |
| Abid, F | 1 |
| Saxonhouse, SJ | 1 |
| Friberg, J | 1 |
| Gadsbøll, N | 1 |
| Fynn, SP | 1 |
| Todd, DM | 1 |
| Hobbs, WJ | 1 |
| Armstrong, KL | 1 |
| Fitzpatrick, AP | 1 |
| Garratt, CJ | 1 |
| Mitchell, AR | 1 |
| Spurrell, PA | 1 |
| Sulke, N | 1 |
| Tai, CT | 3 |
| Tsai, CF | 2 |
| Lin, WS | 1 |
| Tsao, HM | 1 |
| Huang, JL | 1 |
| Ueng, KC | 1 |
| Yu, WC | 2 |
| Chan, P | 1 |
| Ding, YA | 2 |
| Chang, MS | 3 |
| Molina, RT | 1 |
| Scapín, AO | 1 |
| Blanco, MV | 1 |
| Klein, GJ | 2 |
| Krahn, AD | 2 |
| Yee, R | 2 |
| Zarnke, K | 2 |
| Simpson, C | 2 |
| Skanes, A | 2 |
| Dorian, P | 4 |
| Mangat, I | 1 |
| Hermida, JS | 3 |
| Jarry, G | 3 |
| Tcheng, E | 3 |
| Moullart, V | 3 |
| Arlot, S | 3 |
| Rey, JL | 3 |
| Delonca, J | 2 |
| Schvartz, C | 3 |
| Ryan, LE | 1 |
| Braverman, LE | 1 |
| Cooper, DS | 1 |
| Ladenson, PW | 1 |
| Kloos, RT | 1 |
| Hauser, TH | 1 |
| Pinto, DS | 1 |
| Josephson, ME | 4 |
| Zimetbaum, P | 1 |
| Willems, S | 1 |
| Ventura, R | 1 |
| Weiss, C | 1 |
| Risius, T | 1 |
| Nogami, A | 1 |
| Naito, S | 1 |
| Kaneko, T | 1 |
| Aiba, T | 3 |
| Shimizu, W | 3 |
| Inagaki, M | 1 |
| Satomi, K | 2 |
| Taguchi, A | 3 |
| Suyama, K | 3 |
| Aihara, N | 3 |
| Sunagawa, K | 1 |
| Kamakura, S | 3 |
| Bertaglia, E | 1 |
| Bonso, A | 2 |
| Zoppo, F | 1 |
| Verlato, R | 1 |
| Corò, L | 1 |
| Mantovan, R | 1 |
| Raviele, A | 2 |
| Pascotto, P | 1 |
| Lad, V | 1 |
| Ventura, M | 1 |
| Elvas, L | 1 |
| Providência, L | 1 |
| Tsagalou, EP | 1 |
| Kanakakis, J | 1 |
| Rokas, S | 1 |
| Anastasiou-Nana, MI | 1 |
| Hersi, A | 1 |
| Wyse, DG | 1 |
| Clement, CI | 1 |
| Myers, P | 1 |
| Tan, KP | 1 |
| Kozák, M | 1 |
| Izákovicová Hollá, L | 1 |
| Krivan, L | 1 |
| Vasků, A | 1 |
| Sepsi, M | 1 |
| Semrád, B | 1 |
| Vácha, J | 1 |
| Benchimol Barbosa, PR | 1 |
| de Souza Bomfim, A | 2 |
| Barbosa, EC | 2 |
| Ginefra, P | 2 |
| Helena Cardoso Boghossian, S | 1 |
| Destro, C | 1 |
| Nadal, J | 1 |
| Kosior, DA | 1 |
| Wozakowska-Kaplon, B | 1 |
| Rabczenko, D | 1 |
| Sticherling, C | 1 |
| Behrens, S | 1 |
| Kamke, W | 1 |
| Stahn, A | 1 |
| Zabel, M | 1 |
| Salamé, E | 2 |
| Osta, H | 1 |
| Antonios, S | 1 |
| Abdel-Massih, T | 1 |
| Gerbaka, B | 1 |
| Kassab, R | 1 |
| Gorenek, B | 1 |
| Cavusoglu, Y | 1 |
| Goktekin, O | 1 |
| Birdane, A | 1 |
| Kudaiberdieva, G | 1 |
| Ata, N | 1 |
| Unalir, A | 1 |
| Timuralp, B | 1 |
| Chilov, MN | 1 |
| Moshegov, CN | 1 |
| Booth, F | 1 |
| Pappone, C | 1 |
| Good, E | 1 |
| Bogun, F | 1 |
| Bates, ER | 1 |
| Lehmann, MH | 1 |
| Vicedomini, G | 1 |
| Augello, G | 1 |
| Agricola, E | 1 |
| Sala, S | 1 |
| Santinelli, V | 1 |
| Sugi, K | 1 |
| Janko, S | 1 |
| Hoffmann, E | 2 |
| Elikowski, W | 1 |
| Cofta, S | 1 |
| Nowicki, A | 1 |
| Mańczak, J | 1 |
| Psuja, P | 1 |
| Przybylski, A | 1 |
| Derejko, P | 1 |
| Iwanek, M | 1 |
| Urbanek, P | 1 |
| Kepski, R | 1 |
| Grzybowski, J | 1 |
| Chojnowska, L | 1 |
| Szumowski, Ł | 1 |
| Szwed, H | 1 |
| Walczak, F | 1 |
| Kafkas, NV | 1 |
| Patsilinakos, SP | 1 |
| Mertzanos, GA | 1 |
| Papageorgiou, KI | 1 |
| Chaveles, JI | 1 |
| Dagadaki, OK | 1 |
| Kelesidis, KM | 1 |
| Bobbio, A | 1 |
| Caporale, D | 1 |
| Internullo, E | 1 |
| Ampollini, L | 1 |
| Bettati, S | 1 |
| Rossini, E | 1 |
| Carbognani, P | 1 |
| Rusca, M | 1 |
| Martínez-Brotóns, AM | 1 |
| Ruiz-Granell, R | 1 |
| Morell, S | 1 |
| Plancha, E | 1 |
| Ferrero, A | 1 |
| Roselló, A | 1 |
| Llácer, A | 1 |
| García-Civera, R | 1 |
| Okayasu, K | 1 |
| Takeda, Y | 1 |
| Kojima, J | 1 |
| Yoshizawa, A | 1 |
| Kobayashi, N | 1 |
| Sugiyama, H | 1 |
| Kudo, K | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Nedostup, AV | 1 |
| Vasiukov, SS | 1 |
| Fedorova, VI | 1 |
| Gordeev, SA | 1 |
| Yamagata, K | 1 |
| Noda, T | 1 |
| Okamura, H | 1 |
| Olshansky, B | 1 |
| Poole, JE | 1 |
| Johnson, G | 1 |
| Anderson, J | 1 |
| Hellkamp, AS | 1 |
| Packer, D | 1 |
| Mark, DB | 1 |
| Lee, KL | 1 |
| Bardy, GH | 1 |
| Pelleg, A | 2 |
| Miller, HI | 2 |
| Laniado, S | 2 |
| Menozzi, C | 2 |
| Lolli, G | 2 |
| Monducci, I | 2 |
| Gheller, G | 1 |
| Brignole, M | 2 |
| Vergoni, W | 1 |
| Barone, A | 1 |
| Cattabiani, ML | 1 |
| Guiducci, U | 1 |
| Saksena, S | 2 |
| Rothbart, ST | 1 |
| Cappello, G | 1 |
| Marcus, FI | 1 |
| Scheinman, MM | 7 |
| Shen, E | 1 |
| Shapiro, W | 1 |
| Sung, RJ | 2 |
| DiCarlo, L | 1 |
| McGovern, B | 2 |
| Garan, H | 2 |
| Kelly, E | 1 |
| Ruskin, JN | 2 |
| Hancock, EW | 1 |
| Rotmensch, HH | 2 |
| Swanson, BN | 1 |
| Shoshani, D | 1 |
| Spielman, SR | 3 |
| Greenspon, AJ | 2 |
| Greenspan, AM | 3 |
| Vlasses, PH | 1 |
| Horowitz, LN | 3 |
| Manresa, F | 1 |
| Dorca, J | 1 |
| Rodriguez Sanchon, B | 1 |
| Romero Colomer, P | 1 |
| Roussane, A | 1 |
| Blanc, P | 1 |
| Virot, P | 1 |
| Doumeix, JJ | 1 |
| Chabanier, A | 1 |
| Bensaid, J | 1 |
| Blanc, G | 1 |
| Sauve, MJ | 3 |
| Malone, P | 3 |
| Shen, EN | 1 |
| Schwartz, AB | 1 |
| Bhandari, A | 1 |
| Keung, E | 1 |
| Shapira, J | 1 |
| Paredes, A | 1 |
| Ashkenazi, B | 1 |
| Fajuri, A | 2 |
| González, R | 2 |
| Diáz, R | 1 |
| Arriagada, D | 1 |
| Corbalán, R | 1 |
| Joelson, J | 1 |
| Kluger, J | 1 |
| Cole, S | 1 |
| Conway, M | 1 |
| Malacoff, RF | 1 |
| DiMarco, JP | 4 |
| Grant, G | 1 |
| Sellers, TD | 1 |
| Rasmussen, K | 1 |
| Winkle, R | 1 |
| Ross, D | 1 |
| Griffin, J | 1 |
| Peters, F | 1 |
| Mason, J | 1 |
| Kaski, JC | 1 |
| Girotti, LA | 1 |
| Messuti, H | 1 |
| Rutitzky, B | 1 |
| Rosenbaum, MB | 1 |
| Heger, JJ | 4 |
| Warfel, KA | 1 |
| Rinkenberger, RL | 1 |
| Zipes, DP | 5 |
| Mattison, P | 1 |
| Rodger, JC | 1 |
| Nademanee, K | 3 |
| Singh, BN | 4 |
| Hendrickson, J | 1 |
| Intarachot, V | 1 |
| Lopez, B | 1 |
| Feld, G | 1 |
| Weiss, JL | 1 |
| Cabanis, C | 1 |
| Lardoux, H | 1 |
| Guize, L | 2 |
| Lairy, G | 1 |
| Maurice, P | 1 |
| Lubbe, WF | 1 |
| Mercer, CJ | 1 |
| Roche, AH | 1 |
| Lowe, JB | 1 |
| Mason, JW | 1 |
| Swerdlow, CD | 1 |
| Winkle, RA | 3 |
| Griffin, JC | 2 |
| Ross, DL | 1 |
| Keefe, DL | 1 |
| Clusin, WT | 1 |
| Hendrickson, JA | 1 |
| Reed, AW | 1 |
| Melmed, S | 1 |
| Hershman, J | 1 |
| Welch, WJ | 1 |
| Strasberg, B | 3 |
| Coelho, A | 1 |
| Rosen, KM | 1 |
| Moncini, S | 1 |
| Piccone, U | 1 |
| Frustaglia, A | 1 |
| Hamer, AW | 1 |
| Finerman, WB | 1 |
| Peter, T | 2 |
| Mandel, WJ | 1 |
| Waleffe, A | 1 |
| Mary-Rabine, L | 1 |
| Legrand, V | 1 |
| Demoulin, JC | 1 |
| Kulbertus, HE | 1 |
| Nasir, N | 1 |
| Doyle, TK | 1 |
| Wheeler, SH | 1 |
| Pacifico, A | 3 |
| Donado Uña, JR | 1 |
| López Encuentra, A | 1 |
| Echave-Sustaeta, JM | 1 |
| Levine, JH | 3 |
| Herre, JM | 3 |
| Lindsay, BD | 1 |
| Plumb, VJ | 1 |
| Janosik, DL | 1 |
| Kopelman, HA | 3 |
| Friehling, T | 1 |
| Chilson, DA | 2 |
| Platia, EV | 3 |
| Wilber, DJ | 1 |
| Konstantinova, TV | 1 |
| Legkonogov, AV | 1 |
| Savchuk, OM | 1 |
| Siebels, J | 1 |
| Cappato, R | 1 |
| Rüppel, R | 1 |
| Schneider, MA | 1 |
| Kuck, KH | 1 |
| Chun, SH | 1 |
| Sager, PT | 1 |
| Middlekauff, HR | 1 |
| Pisapia, A | 1 |
| Bine-Scheck, F | 1 |
| Schenowitz, A | 1 |
| Domerego, JJ | 1 |
| Maraud, L | 1 |
| Canler, A | 1 |
| Labban, N | 1 |
| Viart, R | 1 |
| Aubry, P | 1 |
| Beruben, E | 1 |
| Facchin, D | 2 |
| Feruglio, GA | 2 |
| Nucifora, R | 1 |
| Bellone, P | 1 |
| Spirito, P | 2 |
| Vecchio, C | 1 |
| Kochs, M | 1 |
| Eggeling, T | 1 |
| Hombach, V | 1 |
| Vanuzzo, D | 1 |
| Russo, AM | 1 |
| Beauregard, LM | 1 |
| Waxman, HL | 3 |
| Koenig, A | 1 |
| Theolade, R | 1 |
| Chauvin, M | 1 |
| Brechenmacher, C | 1 |
| Bellandi, F | 1 |
| Cantini, F | 1 |
| Pedone, T | 1 |
| Dabizzi, RP | 1 |
| Palchetti, R | 1 |
| Ahsan, A | 1 |
| Aldridge, R | 1 |
| Bowes, R | 1 |
| Weinberg, BA | 1 |
| Miles, WM | 2 |
| Klein, LS | 2 |
| Bolander, JE | 1 |
| Dusman, RE | 1 |
| Stanton, MS | 1 |
| Langefeld, C | 1 |
| Pfisterer, ME | 1 |
| Kiowski, W | 1 |
| Brunner, H | 1 |
| Burckhardt, D | 2 |
| Burkart, F | 1 |
| Massumi, A | 1 |
| Gomes, A | 1 |
| Woosley, RL | 1 |
| Chendrasekhar, A | 1 |
| Barke, RA | 1 |
| Druck, P | 1 |
| Rapezzi, C | 1 |
| Maragnès, P | 1 |
| Villain, E | 2 |
| Iselin, M | 1 |
| David, N | 1 |
| Foucault, JP | 1 |
| Tonet, J | 1 |
| Hidden, F | 1 |
| Naditch, L | 1 |
| Coutte, R | 1 |
| Himbert, C | 1 |
| Frank, R | 1 |
| Bourret, N | 1 |
| Kirkorian, G | 1 |
| Chevalier, P | 1 |
| Bellon, C | 1 |
| Richalet, C | 1 |
| Bouchayer, D | 1 |
| Bonnefoy, E | 1 |
| Touboul, P | 1 |
| Ammann, R | 1 |
| Braathen, LR | 1 |
| Stanisławska, J | 1 |
| Górecki, A | 1 |
| Swiecicka, G | 1 |
| Torbicki, A | 1 |
| Kraska, T | 1 |
| Winters, SL | 1 |
| Sachs, RG | 1 |
| Curwin, JH | 1 |
| Leenhardt, A | 1 |
| Thomas, O | 1 |
| Coumel, P | 2 |
| Meierhenrich, R | 1 |
| Helguera, ME | 1 |
| Kidwell, GA | 1 |
| Tebbe, U | 1 |
| Eckardt, L | 1 |
| Breithardt, G | 2 |
| Bart, BIa | 1 |
| Mamtsev, BN | 1 |
| Larin, VG | 1 |
| Smirnova, OL | 1 |
| Duytschaever, M | 1 |
| Haerynck, F | 1 |
| Tavernier, R | 1 |
| Jordaens, L | 1 |
| Halawa, B | 1 |
| Kochiadakis, GE | 3 |
| Igoumenidis, NE | 3 |
| Marketou, ME | 3 |
| Solomou, MC | 1 |
| Kanoupakis, EM | 1 |
| Vardas, PE | 3 |
| Connolly, SJ | 2 |
| Fries, R | 1 |
| Heisel, A | 1 |
| Schieffer, H | 1 |
| Leak, D | 3 |
| Humphries, JO | 1 |
| Matiushin, GV | 1 |
| Shul'man, VA | 1 |
| Balog, AI | 1 |
| Golovenkin, SE | 1 |
| Smirnova, OV | 1 |
| Levy, S | 2 |
| Prakash, VS | 1 |
| Gabal-Shehab, LL | 1 |
| Monga, M | 1 |
| Lane, J | 1 |
| Van Hare, GF | 1 |
| López-Gómez, D | 1 |
| Nicolás, J | 1 |
| Frigola, JM | 1 |
| Manito, N | 1 |
| Esplugas, E | 1 |
| Bonnet, D | 1 |
| Acar, P | 1 |
| Aggoun, Y | 1 |
| Sidi, D | 1 |
| Kachaner, J | 1 |
| Kavesh, NG | 1 |
| Olsovsky, MR | 1 |
| Freudenberger, RS | 1 |
| Conte, JV | 1 |
| Peters, RW | 1 |
| Shorofsky, SR | 1 |
| Gold, MR | 1 |
| Noble, SL | 1 |
| Replogle, WH | 1 |
| Dickey, SR | 1 |
| Tomcsányi, J | 1 |
| Merkely, B | 1 |
| Tenczer, J | 1 |
| Papp, L | 1 |
| Karlócai, K | 1 |
| Kirkali, Z | 1 |
| Blommaert, D | 1 |
| De Roy, L | 1 |
| Adam, JF | 1 |
| Jamart, J | 1 |
| Mucumbitsi, J | 1 |
| Rabe, J | 1 |
| Kulinna, W | 1 |
| Lehmann, KJ | 1 |
| Georgi, M | 1 |
| Katariya, K | 1 |
| DeMarchena, E | 1 |
| Bolooki, H | 1 |
| Chen, CC | 1 |
| Hsu, TL | 1 |
| Kaufmann, R | 1 |
| Fogel, RI | 2 |
| Trohman, RG | 1 |
| Fineberg, N | 2 |
| Lüderitz, B | 2 |
| Edwards, KE | 1 |
| Wenstone, R | 1 |
| Kaleboubas, MD | 2 |
| Simantirakis, EN | 1 |
| Villani, GQ | 1 |
| Piepoli, MF | 1 |
| Terracciano, C | 1 |
| Cooley, R | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Cioffi, G | 1 |
| Cemin, C | 1 |
| Russo, TE | 1 |
| Pellegrini, A | 1 |
| Terrasi, F | 1 |
| Ferrario, G | 1 |
| Spindler, B | 1 |
| Van Noord, T | 1 |
| Van Gelder, IC | 3 |
| Schoonderwoerd, BA | 1 |
| Chrysostomakis, SI | 1 |
| Mavrakis, HE | 1 |
| Barbosa, PR | 1 |
| Boghossian, SH | 1 |
| da Rocha, PJ | 1 |
| Filho, FM | 1 |
| Michelucci, A | 1 |
| Lazzeri, C | 1 |
| Padeletti, L | 1 |
| Bagliani, G | 1 |
| Colella, A | 1 |
| Sabini, A | 1 |
| Zipoli, R | 1 |
| Costoli, A | 1 |
| Pieragnoli, P | 1 |
| Gensini, GF | 1 |
| Franchi, F | 1 |
| Reithmann, C | 1 |
| Dorwarth, U | 1 |
| Gerth, A | 1 |
| Remp, T | 1 |
| Steinbeck, G | 1 |
| Sanders, GD | 1 |
| Hlatky, MA | 1 |
| Every, NR | 1 |
| McDonald, KM | 1 |
| Heidenreich, PA | 1 |
| Parsons, LS | 1 |
| Owens, DK | 1 |
| Shiga, T | 2 |
| Wakaumi, M | 2 |
| Matsuda, N | 2 |
| Shoda, M | 2 |
| Hagiwara, N | 2 |
| Kasanuki, H | 2 |
| Jeantet, M | 1 |
| Losay, J | 1 |
| Cassinat, G | 1 |
| Andral, J | 1 |
| de Pouvourville, G | 1 |
| Cass, D | 1 |
| Schwartz, B | 1 |
| Cooper, R | 1 |
| Gelaznikas, R | 1 |
| Barr, A | 1 |
| Brembilla-Perrot, B | 1 |
| Claudon, O | 1 |
| Houriez, P | 1 |
| Beurrier, D | 1 |
| Suty-Selton, C | 1 |
| Biffi, M | 1 |
| Boriani, G | 1 |
| Bartolotti, M | 1 |
| Bacchi Reggiani, L | 1 |
| Zannoli, R | 1 |
| Branzi, A | 1 |
| Imai, T | 1 |
| Suzuki, T | 1 |
| Hosaka, F | 1 |
| Yamada, Y | 1 |
| Sugiura, R | 1 |
| Paquette, M | 1 |
| Newman, D | 1 |
| Green, M | 1 |
| Talajic, M | 1 |
| Krikler, D | 1 |
| Rosen, MR | 1 |
| Wellens, HJ | 1 |
| Eydt, JN | 2 |
| Husson, J | 1 |
| Shenasa, M | 1 |
| Checrallah, E | 1 |
| Abou Jaoudé, S | 1 |
| Halaby, J | 1 |
| Handlin, LR | 1 |
| Brodine, WN | 1 |
| Gibbs, H | 1 |
| Vacek, JL | 1 |
| Fouchard, J | 1 |
| Le, F | 1 |
| Py, A | 1 |
| Guérin, F | 1 |
| Arstall, MA | 1 |
| Hii, JT | 1 |
| Lehman, RG | 1 |
| Horowitz, JD | 1 |
| Lauribe, P | 1 |
| Dolla, E | 1 |
| Kou, W | 1 |
| Kadish, A | 1 |
| Calkins, H | 1 |
| Pagannelli, F | 1 |
| Moyal, C | 1 |
| Bremondy, M | 1 |
| Schork, A | 1 |
| Dabrowski, A | 1 |
| Gavaliatsis, IP | 1 |
| Kouvousis, NM | 1 |
| Rallidis, LS | 1 |
| Pirros, JM | 1 |
| Dionisopoulou, CT | 1 |
| Tsitouris, GK | 1 |
| Villani, R | 1 |
| Zoletti, F | 1 |
| Veniani, M | 1 |
| Locati, F | 1 |
| Nava, S | 2 |
| Gosselink, AT | 1 |
| Hillige, H | 1 |
| Wiesfeld, AC | 1 |
| Lie, KI | 2 |
| Manz, M | 2 |
| Jung, W | 1 |
| Knilans, TK | 1 |
| Evans, SJ | 1 |
| Myers, M | 1 |
| Zaher, C | 1 |
| Simonson, J | 1 |
| Nalos, P | 1 |
| Vaughn, C | 1 |
| Oseran, D | 1 |
| Gang, E | 1 |
| Mandel, W | 1 |
| Somberg, J | 1 |
| Kreamer, J | 1 |
| Camba, N | 1 |
| Van Gilst, WH | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Shannon, JA | 1 |
| Hammill, SC | 1 |
| Gersh, BJ | 1 |
| Nalos, PC | 1 |
| Ismail, Y | 1 |
| Pappas, JM | 1 |
| Nyitray, W | 1 |
| DonMichael, TA | 1 |
| Lawrie, GM | 1 |
| Kaushik, R | 1 |
| Nahas, C | 1 |
| Earle, N | 1 |
| Di Pede, F | 1 |
| Gasparini, G | 1 |
| Caprioglio, F | 1 |
| Zanocco, A | 1 |
| Delise, P | 1 |
| D'Este, D | 1 |
| Piccolo, E | 1 |
| McAlister, HF | 1 |
| Luke, RA | 1 |
| Whitlock, RM | 1 |
| Smith, WM | 1 |
| Scanavacca, MI | 1 |
| Sosa, EA | 1 |
| Lee, JH | 1 |
| Bellotti, G | 1 |
| Pileggi, F | 1 |
| Guccione, P | 1 |
| Paul, T | 1 |
| Garson, A | 1 |
| Robinson, K | 1 |
| Frenneaux, MP | 1 |
| Stockins, B | 1 |
| Karatasakis, G | 1 |
| Poloniecki, JD | 1 |
| McKenna, WJ | 1 |
| Haines, DE | 2 |
| Lucet, V | 1 |
| Do Ngoc, D | 1 |
| Denjoy, I | 1 |
| Saby, MA | 1 |
| Toumieux, MC | 1 |
| Batisse, A | 1 |
| Kusniec, J | 1 |
| Zlotikamien, B | 1 |
| Mager, A | 1 |
| Sclarovsky, S | 2 |
| Best, JF | 1 |
| Rinkenberger, R | 1 |
| Lynch, L | 1 |
| Dunn, M | 1 |
| Bogers, AJ | 1 |
| Quaegebeur, JM | 1 |
| Ottenkamp, J | 1 |
| Huysmans, HA | 1 |
| Gössinger, HD | 1 |
| Siostrzonek, P | 1 |
| Wagner, L | 1 |
| Leitha, T | 1 |
| Mösslacher, H | 1 |
| Arriagada, C | 1 |
| Marchesse, M | 1 |
| Serrat, H | 1 |
| Aonuma, K | 1 |
| Rozanski, JJ | 1 |
| Barold, SS | 1 |
| DeWitt, PL | 1 |
| Gosselin, AJ | 1 |
| Lister, JW | 1 |
| Gembruch, U | 1 |
| Bald, R | 1 |
| Rüddel, H | 1 |
| Redel, DA | 1 |
| Schlebusch, H | 1 |
| Nitsch, J | 1 |
| Hansmann, M | 1 |
| Schützenberger, W | 1 |
| Leisch, F | 1 |
| Kerschner, K | 1 |
| Harringer, W | 1 |
| Herbinger, W | 1 |
| Salamon, E | 1 |
| Rowe, RC | 1 |
| Faiman, C | 1 |
| Manolis, AS | 1 |
| Uricchio, F | 1 |
| Williams, ML | 1 |
| Woelfel, A | 1 |
| Cascio, WE | 1 |
| Simpson, RJ | 1 |
| Gettes, LS | 1 |
| Foster, JR | 1 |
| Parra, O | 1 |
| Ruiz, J | 1 |
| Ojanguren, I | 1 |
| Navas, JJ | 1 |
| Morera, J | 1 |
| Vorob'ev, LP | 1 |
| Kaziulin, AN | 1 |
| Helmy, I | 1 |
| Langberg, JJ | 1 |
| Goldberg, H | 1 |
| Purcaro, A | 1 |
| Capestro, F | 1 |
| Ciampani, N | 1 |
| Fratadocchi, GB | 1 |
| Mazzanti, M | 1 |
| Costantini, C | 1 |
| Molini, E | 1 |
| Anastasio, R | 1 |
| Facchin, L | 1 |
| Gualandi, G | 1 |
| Zannini, L | 1 |
| Caturelli, G | 1 |
| Friehling, TD | 1 |
| Marinchak, RA | 1 |
| Sulpizi, AM | 1 |
| Stohler, JL | 1 |
| Volosin, KJ | 1 |
| Greenberg, RM | 1 |
| Jefferies, L | 1 |
| Klein, RC | 1 |
| Machell, C | 1 |
| Rushforth, N | 1 |
| Standefur, J | 1 |
| Kammerling, JM | 1 |
| Bellocci, F | 1 |
| Santarelli, P | 1 |
| Montenero, S | 1 |
| Nobile, A | 1 |
| Spampinato, A | 1 |
| Zecchi, P | 1 |
| Manzoli, U | 1 |
| Hwang, YS | 1 |
| Musiał, WJ | 1 |
| Bolińska, H | 1 |
| Radzikowska-Wasiak, M | 1 |
| Polak-Słaboszewska, D | 1 |
| Rey, E | 1 |
| Bachrach, LK | 1 |
| Burrow, GN | 1 |
| Greenberg, ML | 1 |
| Lerman, BB | 2 |
| Shipe, JR | 1 |
| Kaiser, DL | 1 |
| Kadish, AH | 2 |
| Buxton, AE | 3 |
| Flores, B | 1 |
| Cañas, M | 1 |
| Rosselot, I | 1 |
| Bahamonde, L | 1 |
| Rosselot, E | 1 |
| Schmitt, C | 1 |
| Brachmann, J | 1 |
| Waldecker, B | 1 |
| Senges, J | 1 |
| Kübler, W | 1 |
| Brodsky, MA | 1 |
| Allen, BJ | 1 |
| Walker, CJ | 1 |
| Casey, TP | 1 |
| Luckett, CR | 1 |
| Henry, WL | 1 |
| Zhu, J | 1 |
| Fogoros, RN | 1 |
| Fiedler, SB | 1 |
| Elson, JJ | 1 |
| Scardi, S | 1 |
| Ciani, F | 1 |
| Pandullo, C | 1 |
| Padrini, R | 1 |
| Pivotti, F | 1 |
| Lavery, D | 1 |
| Salerno, JA | 1 |
| Bressan, MA | 1 |
| Vigano, M | 1 |
| Chimienti, M | 1 |
| Previtali, M | 1 |
| Martinelli, L | 1 |
| Pagnin, A | 1 |
| Montemartini, C | 1 |
| Bobba, P | 1 |
| Kushakovskiĭ, MS | 1 |
| Uzilevskaia, RA | 1 |
| Fineberg, NS | 1 |
| Duncan, G | 1 |
| Buchanan, D | 1 |
| Gillette, PC | 1 |
| Zinner, A | 1 |
| Crawford, F | 1 |
| Sokoloff, NM | 2 |
| Rae, AP | 2 |
| Brady, PM | 1 |
| Kay, HR | 2 |
| Webb, CR | 1 |
| Morganroth, J | 1 |
| Rotmensch, H | 1 |
| Segal, BL | 1 |
| DiCarlo, LA | 1 |
| Davis, JC | 1 |
| Evans-Bell, T | 1 |
| Winston, SA | 1 |
| Veltri, EP | 1 |
| Reid, PR | 1 |
| Griffith, LS | 1 |
| Flores, BT | 1 |
| Doherty, JU | 1 |
| Pidrman, V | 1 |
| Arditti, A | 1 |
| Lewin, RF | 1 |
| Buimovici, B | 1 |
| Agmon, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, International, Multi-center, Open-label Study to Document Optimal Timing of Initiation of Dronedarone Treatment After Conversion With Loading Dose of Amiodarone in Patients With Persistent Atrial Fibrillation Requiring Conversion of AF.[NCT01140581] | Phase 4 | 402 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Randomized, International, Multi-center, Open-label Study to Document Pharmacokinetics and Optimal Timing of Initiation of Dronedarone Treatment Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Whatever the Re[NCT01199081] | Phase 4 | 154 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion[NCT01991119] | 98 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation (ICM REDUCE-AF)[NCT04922281] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-02-28 | Recruiting | ||
| Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation[NCT01173809] | Phase 3 | 176 participants (Anticipated) | Interventional | 2010-10-31 | Completed | ||
| Anti-Arrhythmic Medication (Amiodarone) Post Surgical Ablation for Atrial Fibrillation - Is it Necessary?[NCT01416935] | 186 participants (Actual) | Interventional | 2011-01-01 | Terminated | |||
| Endocardial-Epicardial Radiofrequency Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy[NCT04512911] | Early Phase 1 | 0 participants (Actual) | Interventional | 2023-01-31 | Withdrawn (stopped due to IRB approval expired 1/23/2023 and eclipsed the 6 month institutional window where study can be reinitiated via progress report. No enrollment has taken place.) | ||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT03819504] | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Change in the design of the study) | |||
| Phase I/II Study of 4-D Navigated Non-invasive Radiosurgical Ablation of Ventricular Tachycardia[NCT03601832] | 10 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| VOYAGE- Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance[NCT04694079] | Phase 3 | 103 participants (Anticipated) | Interventional | 2020-08-03 | Recruiting | ||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT04612140] | 100 participants (Actual) | Interventional | 2020-10-01 | Completed | |||
| Ventricular Tachycardia Ablation or Escalated aNtiarrhythmic Drugs in ISchemic Heart Disease[NCT00905853] | Phase 4 | 260 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Repeated Endocardial Mapping for Efficacy Assessment After Catheter Ablation for Ischemic Ventricular Tachycardia[NCT05713357] | 20 participants (Anticipated) | Observational | 2023-03-15 | Enrolling by invitation | |||
| Initial Management of Patients Receiving a Single Shock (IMPRESS)[NCT03531502] | 30 participants (Actual) | Interventional | 2018-04-09 | Terminated (stopped due to lack of funding) | |||
| Preventive VT Substrate Ablation in Patients With Chronic Post-MI Scar Showing Arrhythmogenic Characteristics[NCT04675073] | Phase 3 | 58 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| An Investigation Into the Effects of Intravenous Lipid Emulsion (ILE) on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.[NCT02924454] | Phase 4 | 10 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence[NCT00376272] | Phase 3 | 1,442 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Evaluating the Efficacy of Circumferential Pulmonary Vein Ablation (CPVA) Versus Segmental Pulmonary Vein Isolation (SPVI) in Paroxysmal Atrial Fibrillation[NCT02106663] | 97 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease[NCT03013257] | 240 participants (Actual) | Interventional | 2017-04-25 | Completed | |||
| Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190] | Phase 3 | 0 participants (Actual) | Interventional | 2017-12-02 | Withdrawn (stopped due to Investigational Medicinal Product Supplies) | ||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Tailored Treatment of Permanent Atrial Fibrillation - TTOP-AF[NCT00514735] | Phase 3 | 210 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI[NCT01182376] | Phase 3 | 33 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [NCT00000609] | Phase 3 | 0 participants | Interventional | 1997-05-31 | Completed | ||
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| Subclinical Postoperative Atrial Fibrillation[NCT02522364] | 150 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients[NCT04539158] | 200 participants (Anticipated) | Interventional | 2020-08-07 | Recruiting | |||
| Double Sequence External Defibrillation: A Randomized Controlled Trial in Patients With Atrial Fibrillation Refractory to DC Cardioversion[NCT03827915] | 100 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A treatment success/failure up to the conclusion of the procedure for each subject in Ablation Management. A subject was considered successfully treated if the following were true:~Medtronic ablation catheters were used to achieve procedure success.~All accessible pulmonary veins were isolated.~At least 50% reduction of complex fractionated atrial electrograms mapped and ablated with Medtronic ablation catheters.~Sinus rhythm was achieved upon leaving the electrophysiology lab (±cardioversion)." (NCT00514735)
Timeframe: Procedure conclusion
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 92.8 |
The primary endpoint for acute safety was a success/failure variable calculated for each subject in Ablation Management at the 7 day post-procedure time point. Any subject with at least one adverse event adjudicated by the Data Safety Monitoring Board as both serious and either probably or definitely procedure and/or device-related occurring within 7 days of the ablation procedure was considered an acute safety failure, regardless of whether the event occurred following the index or retreatment ablation procedure. (NCT00514735)
Timeframe: 7 days
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 12.3 |
"The chronic efficacy endpoint was a treatment success/failure measure for each subject computed at 6 months. Treatment success included:~A 90% reduction in clinically significant atrial fibrillation from baseline to the 6 month time point based on a Holter recording. Clinically significant atrial fibrillation was defined as sustained atrial fibrillation lasting more than 10 minutes.~The subject was off all antiarrhythmic drugs at 6 months (Ablation Management arm only)~The Investigator judged all procedures to be acutely successful (Ablation Management arm only)." (NCT00514735)
Timeframe: 6 months
| Intervention | percentage of participants with success (Number) |
|---|---|
| Ablation Management | 56 |
| Medical Management | 26 |
The primary endpoint for chronic safety was a success/failure variable calculated for each subject at 6 months. Any subject that had at least one adverse event that met designated seriousness and relatedness criteria for the particular treatment group as adjudicated by the Data Safety Monitoring Board was considered a chronic safety failure. Adverse events in Ablation Management that were acute (≤7 days) were not included in the chronic safety primary endpoint. Given the disparity in the length of time at risk between treatment arms,the Chronic Safety endpoint was not statistically powered. (NCT00514735)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Ablation Management | 9 |
| Medical Management | 3 |
The SF-36 questionnaire was administered to subjects at baseline, 1, 3 and 6 month visits. The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based Physical Component Score and Mental Component Score. The possible range for Physical Component Score and Mental Component Score is 0 to 100. The higher score, the better quality of life. (NCT00514735)
Timeframe: 6 months
| Intervention | Scores on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Component Score at Baseline | Physical Component Score at 1 Month | Physical Component Score at 3 Months | Physical Component Score at 6 Months | Mental Component Score at Baseline | Mental Component Score at 1 Month | Mental Component Score at 3 Months | Mental Component Score at 6 Months | |
| Ablation Management | 42.54 | 45.61 | 48.30 | 49.12 | 47.19 | 51.53 | 53.42 | 53.45 |
| Medical Management | 42.26 | 43.05 | 43.99 | 44.98 | 47.99 | 48.96 | 48.97 | 50.06 |
The severity of subject's atrial fibrillation related symptoms on a scale from 1 (no symptoms) to 5 (most severe). The symptoms included palpitations, fatigue, shortness of breath, lightheadedness or dizziness, and lack of energy during exertion or exercise. The scores were tabulated at the 1, 3 and 6 month follow-up visits. Scores could range from 5 to 25, indicating a spectrum of subject status from asymptomatic to severely symptomatic. (NCT00514735)
Timeframe: 6 months
| Intervention | AF Symptom Severity Score (Mean) | |||
|---|---|---|---|---|
| Measurement at Baseline | Measurement at 1 Month | Measurement at 3 Months | Measurement at 6 Months | |
| Ablation Management | 12.38 | 8.95 | 7.56 | 7.58 |
| Medical Management | 12.72 | 9.90 | 10.03 | 9.84 |
Left atrial diameter (LAD), as measured by transthoracic echocardiogram (TTE) looking at the longitudinal long axis at baseline and at the 6 month follow-up visit in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | centimeters (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 4.5 | 4.4 |
| Medical Management | 4.6 | 4.6 |
Left ventricular ejection fraction (LVEF), as measured by transthoracic echocardiogram at baseline and 6 months in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | percent (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 54.7 | 58.3 |
| Medical Management | 54.9 | 57.0 |
The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment. (NCT01182376)
Timeframe: baseline, 1 year
| Intervention | percentage of fibrosis (Mean) |
|---|---|
| Placebo | 24.6 |
| Multaq® (Dronedarone) | 16.8 |
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
36 reviews available for amiodarone and Recrudescence
| Article | Year |
|---|---|
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy | 2020 |
Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Recurrence; Risk Factors; Tachycardia; Thioamides; Thyro | 2019 |
Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Clinical Trial | 2017 |
The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2010 |
Sinus rhythm restoration and treatment success: insight from recent clinical trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as | 2011 |
Dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Dronedarone; Drug Int | 2011 |
Thyrotoxicosis.
Topics: Agranulocytosis; Amiodarone; Antithyroid Agents; Atrial Fibrillation; Autoimmune Diseases; Child; Ex | 2012 |
[Incessant or recurrent ventricular tachycardia. Indications for emergency ablation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Combined Modality Therapy; Contraindications; | 2012 |
[Management of lethal ventricular arrhythmias after cardiac surgery].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiac Surgical Procedures; Cardiop | 2002 |
Risks and benefits of rate control versus maintenance of sinus rhythm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; D | 2003 |
Management of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Algorithms; Amiodarone; Atrial Fibrillation; Heart Rate; Humans; Recurr | 2005 |
Bilateral optic neuropathy due to amiodarone with recurrence.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Optic Nerve Diseases; R | 2005 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
[Strategy for cardiac arrhythmias in acute coronary syndrome].
Topics: Amiodarone; Angina, Unstable; Anti-Asthmatic Agents; Aprindine; Atrial Fibrillation; Bepridil; Elect | 2006 |
[Drug treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Clinical pharmacology of amiodarone.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Benzofurans; Drug Interactions; Heart Ventricles; Humans; | 1984 |
[Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids].
Topics: Amiodarone; Dose-Response Relationship, Drug; Humans; Lung Diseases; Male; Methylprednisolone; Middl | 1995 |
Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
Topics: Action Potentials; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Cal | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; El | 1993 |
Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Humans; Infusions, | 1997 |
[Pharmacological treatment of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1997 |
Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Heart Arrest; Humans; Randomized Co | 1997 |
Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Coronary Artery B | 1998 |
Amiodarone in atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock | 1998 |
Recurrent bilateral amiodarone induced epididymitis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Epididymitis; Humans; Male; Recurrence | 1999 |
[The use of oral amiodarone as a chronic treatment in a patient with prior fulminant hepatitis due to intravenous amiodarone].
Topics: Acute Disease; Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Chemical and Drug Induced L | 1999 |
Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Humans; Multicenter Studies as Topi | 1999 |
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 1999 |
Management of malignant ventricular arrhythmias and cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Defibrillators | 2000 |
How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Evaluation; Electric Stimulation; Electrocardiography, Ambu | 1992 |
Clinical efficacy of long-term treatment with amiodarone for life-threatening arrhythmias.
Topics: Amiodarone; Arrhythmias, Cardiac; Humans; Prospective Studies; Randomized Controlled Trials as Topic | 1992 |
[Isolated atrial fibrillation. The risk of embolism and its prevention].
Topics: 4-Hydroxycoumarins; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Aspirin; Atrial Fibr | 1992 |
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac C | 1990 |
Antiarrhythmic drug therapy in the management of cardiac arrest survivors.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrophysiology; Heart Arrest; Humans; Recurrence | 1992 |
Amiodarone therapy guided by electrophysiologic testing: an update.
Topics: Amiodarone; Arrhythmias, Cardiac; Electric Countershock; Electric Stimulation; Electrophysiology; Hu | 1991 |
[Drug treatment of patients with the chronic form of atrial fibrillation in counterindications for cardioversion (a review)].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anabolic Agents; Atrial Fibrillation; Calcium Channel Block | 1985 |
62 trials available for amiodarone and Recrudescence
| Article | Year |
|---|---|
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Femal | 2020 |
Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study.
Topics: Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Middle Aged; Propafe | 2020 |
Catheter ablation of persistent atrial fibrillation : Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Co | 2018 |
Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial).
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Cat | 2017 |
QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Co | 2019 |
Effect of acupuncture at Neiguan point combined with amiodarone therapy on early recurrence after pulmonary vein electrical isolation in patients with persistent atrial fibrillation.
Topics: Action Potentials; Acupuncture Points; Acupuncture Therapy; Aged; Amiodarone; Anti-Arrhythmia Agents | 2019 |
Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distri | 2014 |
Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Argentina; Atrial Fibrillation; Bayes T | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedaron | 2014 |
Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality | 2014 |
Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE).
Topics: Adrenergic beta-Agonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter A | 2015 |
Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial.
Topics: Ablation Techniques; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Sur | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
[Impact of electrical shock waveform and paddle positions on efficacy of direct current cardioversion for atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Chi-Square Distribut | 2008 |
Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Diuretics; E | 2010 |
Comparison of surgical cut and sew versus radiofrequency pulmonary veins isolation for chronic permanent atrial fibrillation: a randomized study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chronic Disease; F | 2010 |
Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Biphenyl Co | 2010 |
Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Endocrine Disruptors; Feasibili | 2012 |
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
Topics: Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Cross-Over Studies | 2002 |
Intracardiac low-energy versus transthoracic high-energy direct-current cardioversion of atrial fibrillation: a randomised comparison.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatine Kinase; Electric | 2003 |
Effect of amiodarone on dispersion of atrial refractoriness and cycle length in patients with atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; El | 2003 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fib | 2003 |
Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Health Status Indicators; Humans; Propafeno | 2003 |
Serial antiarrhythmic therapy: role of amiodarone in prevention of atrial fibrillation recurrence--a lesson from the HOT CAFE Polish Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans | 2005 |
Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Electric Counters | 2005 |
Amiodarone versus Sotalol and Propafenone for prevention of immediate recurrence of atrial fibrillation after internal cardioversion: importance of P wave analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Male | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.
Topics: Acute Disease; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Respon | 2007 |
Postoperative outcome of patients undergoing lung resection presenting with new-onset atrial fibrillation managed by amiodarone or diltiazem.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Female; Humans; Male; Midd | 2007 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
[New facts about pathogenesis of atrial fibrillation: correlation between changes in bioelectric brain activity and recurrence of atrial fibrillation paroxysms].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticonvulsants; Atrial Fibrillation; Beta Rhythm; Brain; Clonaz | 2007 |
Electrophysiologic study-guided amiodarone for sustained ventricular tachyarrhythmias associated with structural heart diseases.
Topics: Aged; Amiodarone; Death; Electrocardiography, Ambulatory; Electrophysiologic Techniques, Cardiac; Fe | 2008 |
Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Death, Sudden, Cardiac; Defibrillators, | 2008 |
Chronic effects of amiodarone in patients with refractory ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrioventricular Node; Benzofurans; Clinical Trials a | 1983 |
Antiarrhythmic efficacy of amiodarone in recurrent ventricular tachycardia evaluated by multiple electrophysiological and ambulatory ECG recordings.
Topics: Adult; Aged; Amiodarone; Benzofurans; Clinical Trials as Topic; Electrocardiography; Electrophysiolo | 1982 |
Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Bretylium Tosylate; Dose-Response Relationship, Drug; Doub | 1995 |
Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; H | 1995 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
[Value of cibenzoline in the preventive treatment of recurrent atrial arrhythmia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atr | 1994 |
Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction.
Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Follow-Up Studies; Heart Ventricles; Human | 1993 |
Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group.
Topics: Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Bradycardia; Cause of Death; Chi-Square Di | 1996 |
Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome.
Topics: Amiodarone; Anti-Arrhythmia Agents; Coronary Angiography; Coronary Disease; Dose-Response Relationsh | 1997 |
[A trial of the long-term use of Sedacorone (amiodarone) under polyclinic conditions for the prevention of paroxysms of atrial fibrillation].
Topics: Aged; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male | 1997 |
Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Female; Follow-Up Stud | 1998 |
Amiodarone for the treatment of persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; | 1999 |
Limited internal shocks for atrial fibrillation refractory to external cardioversion.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease- | 1999 |
Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Dist | 2000 |
Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Electr | 2000 |
Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Digoxin; | 2000 |
Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart R | 2000 |
Early reinitiation of atrial fibrillation following external electrical cardioversion in amiodarone-treated patients.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Combined | 2001 |
Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Double-Blind Method; Electric C | 2002 |
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Female; Health Status Indicat | 2002 |
[New amiodarone protocol in the treatment of refractory arrhythmias].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
[A comparison between amiodarone and disopyramide in a delayed-release formulation in the prevention of recurrences of symptomatic atrial fibrillation].
Topics: Amiodarone; Analysis of Variance; Atrial Fibrillation; Delayed-Action Preparations; Disopyramide; Fo | 1992 |
Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter.
Topics: Amiodarone; Atrial Fibrillation; Chronic Disease; Clinical Protocols; Electric Countershock; Follow- | 1992 |
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac C | 1990 |
Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Card | 1990 |
[Amiodarone (Cordaron) in the long-term treatment of recurrent supraventricular tachycardia].
Topics: Adolescent; Adult; Aged; Amiodarone; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Re | 1986 |
[Trial of the clinical use of Ritmilen].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyram | 1985 |
221 other studies available for amiodarone and Recrudescence
| Article | Year |
|---|---|
Frontal plane QRS-T angle predicts early recurrence of acute atrial fibrillation after successful pharmacological cardioversion with intravenous amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; H | 2021 |
Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Humans; | 2022 |
Clinical Outcomes in Patients With Dilated Cardiomyopathy and Ventricular Tachycardia.
Topics: Aged; Amiodarone; Cardiomyopathy, Dilated; Catheter Ablation; Female; Humans; Male; Middle Aged; Rec | 2022 |
Mortality after catheter ablation of structural heart disease related ventricular tachycardia.
Topics: Aged; Amiodarone; Catheter Ablation; Humans; Recurrence; Stroke Volume; Tachycardia, Ventricular; Tr | 2023 |
Utility of Amiodarone Pre-Treatment as a Facilitator of the Acute Success of Electrical Cardioversion in Persistent Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Heart | 2020 |
New Onset Recurrent Syncope Triggered by Fever.
Topics: Amiodarone; Coronary Angiography; Drug Therapy, Combination; Electric Countershock; Electrocardiogra | 2020 |
Ventricular tachycardia: beginning and ending fate of a benign invasive cardiac lipoma.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantab | 2020 |
Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter-defibrillator recipients treated with single beta-blocker or combined amiodarone.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Defibrillators, | 2021 |
Optic neuropathy secondary to perhexiline and amiodarone.
Topics: Aged; Amiodarone; Fluorescein Angiography; Humans; Male; Optic Nerve Diseases; Perhexiline; Recurren | 2021 |
Catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: Impact of concomitant amiodarone therapy on short- and long-term clinical outcomes.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Female; Follow-Up Stu | 2021 |
Outcomes after repeat ablation of ventricular tachycardia in structural heart disease: An analysis from the International VT Ablation Center Collaborative Group.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Electric Countershock; Electrocardiogra | 2017 |
Recurrent ventricular fibrillation associated with acute ingestion of hydrofluoric acid.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Blood Pressure; Calcium Gluconate; Fatal Outcome; Female; | 2018 |
Cough as the sole manifestation of pericardial effusion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Cough; Echocardiography; | 2018 |
Ventricular Tachycardia (VT) Storm After Cryoballoon-Based Pulmonary Vein Isolation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cryosurgery; Defibrillators, Implantable; H | 2018 |
Impact of Different Pharmacotherapies on Long-Term Outcomes in Patients with Electrical Storm.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Angiotensin II Type 1 Recep | 2019 |
Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Artery Disease; Drug Evaluation; Drug Resistance; | 2019 |
Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Combined Modality The | 2019 |
Clinical effects of intravenous to oral amiodarone transition strategies in critically ill adult patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 2019 |
Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; D | 2013 |
Catheter ablation of paroxysmal atrial fibrillation in patients with previous amiodarone-induced hyperthyroidism: a case-control study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Cathe | 2013 |
Which patient is most likely to benefit from dronedarone? Analysis from the Magdeburg Dronedarone Registry (MADRE study).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Heart Atria; Hum | 2013 |
Ventricular tachycardia in hypertrophic cardiomyopathy with apical aneurysm successfully treated with left ventricular aneurysmectomy and cryoablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cryosurgery; Diabetes Mellitus, Ty | 2013 |
Predictive value of atrial electromechanical delay for atrial fibrillation recurrence.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Chi-Square Dis | 2013 |
Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein; Female; Humans; I | 2015 |
Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Dronedarone; Evidence-Based Medicin | 2014 |
[Therapeutic use of amiodarone against postoperative fibrillation after cardiac surgery].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Heart Dise | 2014 |
In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Dos | 2014 |
Intravenous amiodarone homogeneously prolongs ventricular repolarization in patients with life-threatening ventricular tachyarrhythmia.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Cond | 2015 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2014 |
[Repeated electrical cardioversions and amiodarone for recurrent neonatal atrial flutter].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Electric Countershock; Humans; Infant, Newborn; | 2015 |
Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; | 2016 |
Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Case-Control Studies; Catheter Ab | 2016 |
Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle | 2016 |
Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Critical Illness; Fem | 2016 |
The use of dronedarone for recurrent ventricular tachycardia: a case report and review of the literature.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Dronedarone; Fatal Outcome | 2016 |
The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distribution; | 2008 |
Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest.
Topics: Adult; Amiodarone; Anesthetics, Local; Anti-Arrhythmia Agents; Brachial Plexus; Bupivacaine; Cardiop | 2009 |
Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Topics: Aged; Aged, 80 and over; Amiodarone; Female; Follow-Up Studies; Goiter; Humans; Hypothyroidism; Iodi | 2009 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Biopsy; Chemical and Drug Induced Liver Injury; Diagnosis, | 2009 |
Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Biomarkers; C-Reactiv | 2010 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
First time and repeat cardioversion of atrial tachyarrhythmias - a comparison of outcomes.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Electric Countershock; Female; Humans; Male; Recurrence; R | 2010 |
Homozygous mutation in SCN5A associated with atrial quiescence, recalcitrant arrhythmias, and poor capture thresholds.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiopulmonar | 2011 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Topics: Algorithms; Amiodarone; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Combined Modality Th | 2011 |
[Unexpected complication following esophageal variceal hemorrhage - Case 2/2011].
Topics: Amiodarone; Anti-Bacterial Agents; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inh | 2011 |
[Treatment of atrial fibrillation: when to use drugs or to perform ablation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic | 2010 |
Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; E | 2011 |
Thyroxine monotherapy without amiodarone enhances atrial fibrillation recurrences in amiodarone-induced hypothyroidism.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Comb | 2011 |
Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia.
Topics: Adenosine; Amiodarone; Catheterization, Central Venous; Combined Modality Therapy; Drug Therapy, Com | 2012 |
[Total body water and recurrent atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Body Water; Female; Humans | 2011 |
Recurrent ventricular tachycardia in a child with juvenile dermatomyositis - an unusual association.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Dermatomyositis; Fatal Outcome; Humans; Immunosuppressive | 2012 |
[Supraventricular extrasystole after cardioversion with amiodarone].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Premature Complex | 2012 |
Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Catheter Ablation; C | 2012 |
[Recurrent failed ICD therapy of ventricular tachycardia].
Topics: Aged; Amiodarone; Anterior Wall Myocardial Infarction; Anti-Arrhythmia Agents; Atrioventricular Node | 2012 |
Effects of dronedarone started rapidly after amiodarone discontinuation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Dronedarone; Drug Substi | 2013 |
Effectiveness and safety of low-energy internal cardioversion of long-standing atrial fibrillation after unsuccessful external cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators, Implantable; Device R | 2002 |
[Sartan improves anti-arrhythmia therapy after cardioversion. Fewer recurrent fibrillation incidents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biphenyl Compounds; Drug Therapy, Combinati | 2002 |
Management of persistent atrial fibrillation following balloon mitral valvotomy: safety and efficacy of low-dose amiodarone.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheterization; Combined Modality T | 2002 |
[Atrial flutter in neonates and infants: diagnosis and treatment].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Echocardiography; Electric Countershock; Electro | 2002 |
Atrial fibrillation storms.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Circadian Rhythm; Defibrillators, Implantab | 2003 |
Clinical outcome of very late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrophys | 2003 |
Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts long-term sinus rhythm maintenance.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Electric Co | 2003 |
Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Iodine Radioisotopes; Male; Middle | 2004 |
Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Iodine Radioisotopes; Male; | 2004 |
Can amiodarone be restarted after amiodarone-induced thyrotoxicosis?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Medical Records; Recurrence; Tachycardia, Ve | 2004 |
[Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hea | 2004 |
Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter.
Topics: Age Factors; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atri | 2004 |
Radiofrequency catheter ablation of a macroreentrant ventricular tachycardia late after surgical repair of tetralogy of Fallot using the electroanatomic mapping (CARTO).
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Catheter Ablation; Cicatrix; | 2004 |
Unidirectional atrio-atrial conduction after surgical isolation of the posterior part of the left atrium and pulmonary veins for atrial fibrillation: simple postsurgical procedure electrophysiological evaluation.
Topics: Adenosine Triphosphate; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cryosurgery; | 2004 |
Excessive increase in QT interval and dispersion of repolarization predict recurrent ventricular tachyarrhythmia after amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Male; Middle Aged; Prognosi | 2004 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
Recurrence of atrial fibrillation and flutter after atrial compartment operation: modified atrial incisions and role of amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cryosurgery; Heart Atria; H | 2005 |
Previous therapy with amiodarone increases the recurrence rate in successfully ablated patients with isthmus-dependent atrial flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Follow-Up Studies; Humans; Re | 2004 |
Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Defibrillator | 2005 |
Endothelin-1 gene polymorphism in patients with malignant arrhythmias.
Topics: Aged; Amino Acid Sequence; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, | 2004 |
Spectral turbulence analysis of the signal-averaged electrocardiogram of the atrial activation as predictor of recurrence of idiopathic and persistent atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Electrocardiography; | 2006 |
[Chaotic atrial tachycardia-induced cardiomyopathy: report of an isolated case].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Female; Humans; Infant, Newborn; Recurrence; T | 2005 |
Unilateral amiodarone keratopathy.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cataract Extraction; Cor | 2005 |
[Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma].
Topics: Aged; Amiodarone; Cardiovascular Agents; Clopidogrel; Coronary Disease; Drug Interactions; Drug Ther | 2005 |
[Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, Implantable; Electrophy | 2006 |
[Therapeutic success of a prospective cardioversion protocol for persistent atrial fibrillation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Protocols; Data Interpretati | 2006 |
Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Body Mass Index; Cardiomyopathy | 2006 |
Serial electrophysiological studies in a young patient with recurrent ventricular fibrillation.
Topics: Adult; Amiodarone; Electrocardiography; Humans; Male; Quinidine; Recurrence; Ventricular Fibrillatio | 1981 |
[Our experience in the electric therapy of sustained ventricular tachycardia and in the provocation test. Subsequent pharmacologic implications].
Topics: Adolescent; Adult; Aged; Amiodarone; Child; Electric Stimulation Therapy; Electrocardiography; Femal | 1984 |
Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Benzofurans; Female; Heart Block; Heart Failure; Humans; Infusions, Parente | 1983 |
Adverse reactions during treatment with amiodarone hydrochloride.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Digoxin; Drug Interactions; Female; Huma | 1983 |
Very wide QRS complexes.
Topics: Aged; Amiodarone; Electrocardiography; Emergencies; Humans; Male; Recurrence; Tachycardia, Paroxysma | 1984 |
Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Dose-Response Relationship, Drug; Female | 1984 |
Recurrent form of amiodarone-induced pneumonitis.
Topics: Aged; Amiodarone; Benzofurans; Humans; Male; Pneumonia; Recurrence | 1984 |
[Long-term fate of 103 patients with auricular fibrillation lasting for over 15 days treated with cardioversion and preventive therapy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Ele | 1984 |
Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Amiodarone; Anorexia; Ataxia; Benzofurans; Female; Heart Arrest; Humans; Lung Diseases; Male; | 1983 |
[Role of electrophysiologic studies in selecting preventive therapy in recurrent, sustained ventricular tachycardia].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Fem | 1983 |
[Electrophysiological evaluation of anti-arrhythmia therapy in patients with recurrent supraventricular and ventricular tachycardia].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Evaluation; Electric Stimulation; Electrocardi | 1983 |
Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Biopsy; Humans; Lung; Male; | 1984 |
Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.
Topics: Aged; Amiodarone; Benzofurans; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Femal | 1984 |
Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Corneal Diseases; Humans; Long-Term Ca | 1981 |
Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.
Topics: Adult; Aged; Amiodarone; Benzofurans; Drug Evaluation; Electric Stimulation; Electrophysiology; Fema | 1981 |
Rapid control of recurrent ventricular tachycardia with oral amiodarone.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Benzofurans; Female; Humans; Male; Recurrence; Tachyc | 1982 |
Amiodarone in refractory life-threatening ventricular arrhythmias.
Topics: Acute Disease; Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrocardiography; Fema | 1983 |
[Supraventricular tachycardias induced by swallowing].
Topics: Adult; Amiodarone; Cardiac Catheterization; Deglutition; Drug Therapy, Combination; Electrocardiogra | 1983 |
Amiodarone in long term management of refractory cardiac tachyarrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Female; Heart Atria | 1981 |
Programmed ventricular stimulation in predicting vulnerability to ventricular arrhythmias and their response to antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardiog | 1982 |
Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy.
Topics: Adult; Aged; Amiodarone; Atrial Flutter; Benzofurans; Electrocardiography; Heart Ventricles; Humans; | 1982 |
Sustained macroreentrant ventricular tachycardia.
Topics: Aged; Amiodarone; Disopyramide; Electrocardiography; Heart Conduction System; Humans; Male; Procaina | 1982 |
[Maintenance of the sinus rhythm after pharmacological cardioversion in the aged].
Topics: Aged; Amiodarone; Atrial Fibrillation; Female; Humans; Hyperthyroidism; Male; Recurrence | 1981 |
Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Cardiac Pacing, Artific | 1981 |
Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia.
Topics: Adult; Amiodarone; Benzofurans; Drug Therapy, Combination; Electric Stimulation; Follow-Up Studies; | 1980 |
Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease.
Topics: Actuarial Analysis; Amiodarone; Cardiac Complexes, Premature; Coronary Disease; Death, Sudden, Cardi | 1994 |
[Case of long-term maintenance of sinus rhythm by means of multiple repeated electric defibrillation].
Topics: Adult; Amiodarone; Atrial Fibrillation; Electric Countershock; Electrocardiography; Humans; Male; Pr | 1995 |
Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Evaluation Studies as Topic; | 1995 |
[Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report].
Topics: Aged; Amiodarone; Bundle-Branch Block; Combined Modality Therapy; Death, Sudden, Cardiac; Defibrilla | 1993 |
Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone.
Topics: Amiodarone; Electric Countershock; Humans; Injections, Intravenous; Lidocaine; Male; Middle Aged; My | 1994 |
Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Angiocardiography; Electrophysiolo | 1993 |
Oral amiodarone loading for the rapid treatment of frequent, refractory, sustained ventricular arrhythmias associated with coronary artery disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Coronary Disease; Drug Resistance; Female | 1993 |
[The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Atrial Fibrillation; Drug Evaluation; Female; Follow- | 1993 |
1:1 atrioventricular conduction in atrial flutter with digoxin and flecainide.
Topics: Aged; Amiodarone; Atrial Flutter; Atrioventricular Node; Digoxin; Drug Therapy, Combination; Electro | 1993 |
Five-year follow-up of 589 patients treated with amiodarone.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Electrophysiology; Female; Follow-Up | 1993 |
Recurrent amiodarone pulmonary toxicity.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Humans; Lung; Male; Recurrence; Respiratory Distress Syndr | 1996 |
Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography, Ambulatory; Electrophysiology; Heart Arrest | 1995 |
[Therapy of arrhythmias in hypertrophic cardiomyopathy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomy | 1995 |
[Late supraventricular arrhythmia complicating Fontan or cavopulmonary type procedures. Apropos of 7 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Atrial Premature Complexes; Cardiac Pacing, Arti | 1996 |
[Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Celiprolol; Chronic Di | 1996 |
[Predictive factors of induction of ventricular arrhythmia under amiodarone].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; | 1996 |
[Amiodarone pigmentation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Eruptions; Female; Humans; Lipofuscin; Long-Term Care; Midd | 1996 |
Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Chronic Disease; Comb | 1997 |
[Etiologies of electric storm].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Bretylium Tosylate; Electric Countershock; Female; Hemodyn | 1997 |
Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electric Countershock; Female; Fol | 1998 |
[Pharmacologic treatment for ventricular arrhythmias].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Coronary Disease; Heart Failure; Humans; Recur | 1997 |
Implantable cardioverter defibrillators--for whom?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Output, Low; Cause of Death; Coronary Artery Bypass; Dec | 1998 |
Influence of beta-blockers on the frequency of arrhythmia recurrences in patients with implantable cardioverter-defibrillator: an intraindividual comparison.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Arrhythmias, Cardiac; Atenolol; Defibrillators, Impla | 1998 |
Amiodarone for control of recurrent ventricular tachycardia secondary to cardiac metastasis.
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Carcinoma, Squamous Cell; Heart Neop | 1998 |
[Combined use of left atrial transesophageal pacing and cordarone in atrial flutter].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Combined Modality Th | 1998 |
Spontaneous termination of ventricular tachycardia with variable patterns and variable mechanisms?
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Electrop | 1999 |
Paroxysmal long RP tachycardia in a three year old: what is the rhythm?
Topics: Amiodarone; Anti-Arrhythmia Agents; Child, Preschool; Diagnosis, Differential; Electrocardiography; | 1999 |
[Recommendations for the treatment of recurrent supraventricular tachycardia in infants].
Topics: Amiodarone; Anti-Arrhythmia Agents; Digoxin; Electric Countershock; Electrocardiography; Humans; Inf | 1998 |
Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Follow-Up Stu | 1999 |
Early proarrhythmia during intravenous amiodarone treatment.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart F | 1999 |
Re: Recurrent bilateral amiodarone induced epididymitis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Epididymitis; Humans; Male; Recurrence | 1999 |
[Dyspnea and thoracic pain. A patient with recurring ventricular arrhythmia].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chest Pain; Dose-Response Relationsh | 1999 |
Oral amiodarone reduces incidence of postoperative atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiopu | 1999 |
Early recurrence of atrial fibrillation after external cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 1999 |
[Atrial fibrillation treated with amidarone].
Topics: Amiodarone; Atrial Fibrillation; Heart Valve Prosthesis Implantation; Humans; Hyperthyroidism; Male; | 1999 |
Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Combined Modality Therapy; Defib | 2000 |
[Paroxysmal atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electric Countershock; F | 2000 |
Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Butanes; Humans; Male; Recurrence; Resuscitation; Su | 2000 |
Post-discharge recurrences of new-onset atrial fibrillation following cardiac surgery: impact of low-dose amiodarone and beta-blocker prophylaxis.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2000 |
Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Electric Counter | 2000 |
The frequency analysis of signal-averaged ECG of P wave as predictor of efficacy of class III antiarrhythmic drugs to maintain sinus rhythm in recurrent idiopathic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; | 2001 |
Altered values of heart rate variability in patients with relapse of atrial fibrillation during the first week after electrical cardioversion: preliminary data.
Topics: Aged; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Electric Countershock; Electrocardiography, | 2001 |
Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benef | 2001 |
Amiodarone-Induced thyroid dysfunction and ventricular tachyarrhythmias during long-term therapy in Japan.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Drug Evaluation; Female; Follow-Up Studies; Humans; H | 2001 |
[Paroxysmal atrial fibrillation in community medicine: management intentions and cost estimates].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2001 |
Long-term efficacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrhythmia and structural heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Follow-Up Studies; Heart Diseases; Humans; Male; Middle | 2002 |
Absence of change of signal-averaged electrocardiogram identifies patients with ventricular arrhythmias who are non-responders to amiodarone.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Electrop | 2002 |
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2002 |
Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; A | 2002 |
Newer antiarrhythmic drugs.
Topics: Administration, Oral; Adult; Amiodarone; Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Ca | 1978 |
Control of refractory cardiac arrhythmias with amiodarone.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Male; Middle Aged; Recur | 1979 |
[Amiodarone, an anti-arrhythmic agent (apropos of a case of ventricular recurrent tachycardia in a coronary patient)].
Topics: Amiodarone; Benzofurans; Coronary Disease; Electrocardiography; Heart Ventricles; Humans; Male; Midd | 1975 |
Slowing of ventricular tachycardia as a possible endpoint for serial drug testing at electrophysiological study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Female; Hear | 1992 |
Sotalol-induced torsade de pointes: management with magnesium infusion.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dose-Response Relationship, Drug; Electrocardiography, Ambula | 1992 |
[Should the patients with atrial fibrillation receive long-term anti-arrhythmia treatment after successful cardioversion?].
Topics: Amiodarone; Atrial Fibrillation; Combined Modality Therapy; Contraindications; Electric Countershock | 1992 |
Recurrent atrial flutter in apical hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Flutter; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Echocardiograp | 1992 |
Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia.
Topics: Aged; Amiodarone; Cardiac Output; Dose-Response Relationship, Drug; Electrocardiography; Female; Hem | 1992 |
High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance.
Topics: Administration, Oral; Amiodarone; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; | 1992 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Predictive value of early electrophysiologic testing in determining long-term outcome with amiodarone treatment in patients with sustained ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Electrophysiology; Evaluation Studies as Topic; Female; Follow-Up Studies; | 1991 |
Intravenous amiodarone for short-term treatment of refractory ventricular tachycardia or fibrillation.
Topics: Aged; Amiodarone; Death, Sudden, Cardiac; Drug Evaluation; Electrocardiography; Female; Humans; Infu | 1991 |
Factors predictive of results of direct ablative operations for drug-refractory ventricular tachycardia. Analysis of 80 patients.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Cardiopulmonary Bypass; Electrophysiology; Female; He | 1991 |
[Empiric treatment with amiodarone in patients with sustained ventricular tachyarrhythmia. Results of a long-term follow-up].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Female; Follow-Up Studies; Heart Ventricles; | 1990 |
[Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia].
Topics: Adult; Aged; Amiodarone; Chagas Cardiomyopathy; Chronic Disease; Female; Heart Rate; Humans; Male; M | 1990 |
Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects.
Topics: Adolescent; Adult; Amiodarone; Arrhythmias, Cardiac; Chemical and Drug Induced Liver Injury; Child; | 1990 |
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Child; Cinea | 1990 |
Sustained intraatrial reentrant tachycardia: clinical, electrocardiographic and electrophysiologic characteristics and long-term follow-up.
Topics: Adenosine; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Electric Stimulation; El | 1990 |
[Esophageal pacing in children. 38 consecutive cases].
Topics: Adolescent; Amiodarone; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Child; Child, Preschool; E | 1990 |
Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone.
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Female; Follow-Up Studies; Heart; Humans; Life Tables; | 1990 |
Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Cardiac Complexes, Premature; Cardiomyopathy, Dilated; | 1986 |
Noninvasive serial electrophysiological testing using an implanted pacemaker for management of recurrent ventricular tachycardia.
Topics: Aged; Amiodarone; Electrophysiology; Heart Ventricles; Humans; Male; Mexiletine; Pacemaker, Artifici | 1986 |
Treatment of ventricular arrhythmia after corrective cardiac surgery in a neonate with intravenous amiodarone.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Female; Humans; Infant, Newborn; Infu | 1987 |
Inadvertent catheter-induced right bundle branch block in a patient with preexistent left bundle branch block and recurrent macroreentrant ventricular tachycardia.
Topics: Aged; Amiodarone; Bundle-Branch Block; Cardiac Catheterization; Electric Stimulation; Electrocardiog | 1989 |
[Idiopathic recurrent ventricular tachycardia: role of verapamil in its treatment].
Topics: Adolescent; Amiodarone; Electrocardiography; Heart Rate; Heart Ventricles; Humans; Middle Aged; Recu | 1989 |
Externally activated antitachycardia pacemaker with noninvasive electrophysiologic re-testing capability.
Topics: Aged; Amiodarone; Atrioventricular Node; Combined Modality Therapy; Electrocardiography; Female; Fol | 1985 |
Repeated intravascular treatment with amiodarone in a fetus with refractory supraventricular tachycardia and hydrops fetalis.
Topics: Adult; Amiodarone; Digoxin; Female; Fetal Diseases; Humans; Hydrops Fetalis; Injections, Intravenous | 1989 |
Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation.
Topics: Amiodarone; Electrocardiography; Female; Heart Ventricles; Humans; Infusions, Intravenous; Male; Mid | 1989 |
Amiodarone-related cyclic thyroid dysfunction.
Topics: Adolescent; Amiodarone; Humans; Hyperthyroidism; Hypothyroidism; Male; Recurrence; Thyroiditis, Auto | 1989 |
Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Coronary Disease; Electric Stimulation; Electrocardiogra | 1989 |
Intravenous amiodarone during prolonged resuscitation from cardiac arrest.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Female; Heart Arrest; Humans; Infusions, Intravenous; In | 1989 |
Amiodarone toxicity: recurrence of interstitial pneumonitis after withdrawal of the drug.
Topics: Amiodarone; Arrhythmias, Cardiac; Humans; Male; Methylprednisolone; Middle Aged; Pulmonary Fibrosis; | 1989 |
Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Amiodarone; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Recurrenc | 1989 |
[Treatment of recurrent supraventricular tachyarrhythmias with flecainide or a flecainide and amiodarone combination].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Drug Therapy, Combination; Electrocardiography; Femal | 1987 |
[Usefulness of pretreatment of patients with atrial fibrillation who are candidates for electric cardioversion].
Topics: Adult; Aged; Amiodarone; Arrhythmia, Sinus; Atrial Fibrillation; Electric Countershock; Female; Huma | 1988 |
Safety and efficacy of amiodarone. The low-dose perspective.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; E | 1988 |
Amiodarone therapy: role of early and late electrophysiologic studies.
Topics: Adult; Aged; Amiodarone; Cardiac Pacing, Artificial; Electrophysiology; Female; Follow-Up Studies; H | 1988 |
Efficacy of intravenous amiodarone as short-term treatment for refractory ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Electrocardiography; Heart Ventricles; Hemodynamics; Humans; Infusions, Int | 1988 |
Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrop
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disea | 1988 |
[The value of electrophysiological studies in the treatment of ventricular tachycardias with amiodarone alone or in combination with class-I anti-arrhythmia drugs].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug | 1988 |
Amiodarone for recurring ventricular arrhythmias: assessment by 24-hour Holter ambulatory electrocardiography.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Female; Heart | 1986 |
Effects of amiodarone during pregnancy.
Topics: Adult; Amiodarone; Female; Heart Ventricles; Humans; Infant, Newborn; Iodine; Maternal-Fetal Exchang | 1987 |
Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Coronary Disease; Dose-Response Relationship, Drug; Electroc | 1987 |
Usefulness of electrophysiologic study to determine the clinical tolerance of arrhythmia recurrences during amiodarone therapy.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrophysiology; Follow-Up Studies; | 1987 |
[Electric cardioversion in the postoperative period after mitral valve surgery].
Topics: Adolescent; Adult; Amiodarone; Atrial Fibrillation; Electric Countershock; Female; Heart Valve Disea | 1986 |
Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment.
Topics: Amiodarone; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Female; Follow-Up Studie | 1987 |
Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Dilated; Female; Heart Atria; Heart Va | 1987 |
Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; Female; Follow | 1987 |
The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias.
Topics: Aged; Amiodarone; Combined Modality Therapy; Death, Sudden; Drug Resistance; Electric Countershock; | 1987 |
[Recurrent alveolitis caused by amiodarone].
Topics: Amiodarone; Benzofurans; Eye Diseases; Female; Humans; Hyperthyroidism; Hypothyroidism; Middle Aged; | 1986 |
Amiodarone: correlation of early and late electrophysiologic studies with outcome.
Topics: Adult; Aged; Amiodarone; Cardiac Pacing, Artificial; Drug Evaluation; Electrocardiography; Female; F | 1986 |
Management of refractory sustained ventricular tachycardia with amiodarone: a reappraisal.
Topics: Administration, Oral; Aged; Ambulatory Care; Amiodarone; Electrocardiography; Female; Humans; Male; | 1987 |
Medical and surgical treatment of sustained and recurrent post-infarction ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Benzofurans; Combined Modality Therapy; Endocardium; Female; Humans; Male; | 1985 |
Amiodarone: risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study.
Topics: Amiodarone; Benzofurans; Electrocardiography; Electrophysiology; Female; Humans; Long-Term Care; Mal | 1985 |
Ventricular tachydysrhythmias in near-miss sudden infant death syndrome.
Topics: Amiodarone; Heart Ventricles; Humans; Infant, Newborn; Infusions, Parenteral; Male; Procainamide; Pr | 1986 |
Amiodarone for refractory cardiac arrhythmias: 10-year study.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Coro | 1986 |
Utility of ambulatory electrocardiographic monitoring for predicting recurrence of sustained ventricular tachyarrhythmias in patients receiving amiodarone.
Topics: Aged; Ambulatory Care; Amiodarone; Benzofurans; Electrocardiography; Female; Heart Ventricles; Human | 1986 |
Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease.
Topics: Adult; Aged; Amiodarone; Benzofurans; Coronary Disease; Electrophysiology; Female; Humans; Male; Mid | 1985 |
Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables.
Topics: Aged; Amiodarone; Analysis of Variance; Benzofurans; Death, Sudden; Female; Heart Arrest; Humans; Ma | 1985 |
Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia.
Topics: Amiodarone; Benzofurans; Cardiac Pacing, Artificial; Electric Stimulation; Electrophysiology; Female | 1985 |
Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone.
Topics: Adult; Aged; Ambulatory Care; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrocardiography; El | 1985 |
Amiodarone and the American Way.
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Drug Evaluation; Electrophysiology; Humans; Recurrenc | 1985 |
[Treatment of resistant, recurrent paroxysmal tachycardias-- contribution of amiodarone].
Topics: Adult; Aged; Amiodarone; Benzofurans; Drug Resistance; Female; Humans; Male; Middle Aged; Recurrence | 1985 |
Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Benzofurans; El | 1985 |